Antisense inhibition of glucose transporter 5 on breast tumor cells. by Chan, Ka Kui. & Chinese University of Hong Kong Graduate School. Division of Biochemistry.
Antisense Inhibition of Glucose Transporter 5 
on Breast Tumor Cells 
By 
CHAN Ka Kui 
A Thesis Submitted in Partial Fulfilment of the Requirements for the 
Degree of Master of Philosophy 
in Biochemistry 
The Chinese University of Hong Kong 
July 2000 
�� 
The Chinese University of Hong Kong holds the copyright of this thesis. Any 
person(s) intending to use a part or whole of the materials in the thesis in a proposed 
publication must seek copyright release from the Dean of the Graduate School. 
I 
i 
/ ^ ^ T ^ ^ V I： 
f / i , / 统 系 馆 書 圓 [ 
•「？ \ • 11 j l j 
~ u n i v e r s i t y j M i. N^^library SYSTEM/^ 丨 
i 
i 










1 would like to give my sinccrc appreciation lo my supervisor, Pmf. K.P. Fung, 
for his whole-hearted aid within this two-year research period, l ie has given mc 
marvelous and valuable ideas thai stimulate and Icach mc how to perform my works. 
I would also like to thank all my friends in BMSB room 316 and in the 
Biochemistry Department. I would not get through this two years easily without their 
warm supports. They also made my school life full of joys and laugh. Thanks my 
parents for their patience and supports. Lastly, thanks God for looking after mc in my 
life. 
Abbreviations 
BCA Bicinchoninic acid 
BCECF 2',7'-bis-[2-carboxyethyl]-5-(and-6)-
carboxyfluorescein 
DEPC Diethyl pyrocarbonate 
FBS Fetal bovine serum 
FITC Fluorescein-5-isothiocyanate 
GAPDH glyceraldehyde-3 -phosphate 
dehydrogenase 
HBSS Hank's buffered salt solution 
MTT Tetrazolium salt 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide 
PBS Phosphate buffered saline 
PFK Phosphofructokinase 
PI Propidium iodide 
PMSF Phenylmethylsulfonyl fluoride 
RT-PCR Reverse transcription-polymerase chain 
reaction 
处MI Roswell Park Memorial Institute tissue 
culture medium 1640 
Antisense Inhibition of Glucose Transporter 5 on Breast Tumor Cells 
Table of contents 
ABSTRACT 1 
1 INTRODUCTION 5 
1.1 Incidence rate of breast cancer in Hong Kong 5 
1 1 Estrogen and breast cancer 6 
1.3 The relation between glucose transporters and breast cancer 7 
1.4 Antisense oligonucleotide 10 
1.5 Action mechanisms of antisense oligonucleotide 11 
1.6 Modification of the oligonucleotide 13 
1.7 Length 16 
1.8 Sequence selection of the antisense oligonucleotide 16 
1.9 Delivery means in antisense oligonucleotide 18 
1.10 The therapeutic role of antisense oligonucleotide 19 
1.11 Obj ective of the proj ect 21 
2 MATERIAL AND METHODS 23 
2.1 Materials 23 
2.2 Methods 26 
3 RESULTS 37 
3.1 The characteristics of MCF-7 and MDA-MB-231 cells 37 
3.2 Trend of uptake of antisense oligonucleotides in MCF-7 and MDA-
MB-231 cells 41 
3.3 The integrity of the oligonucleotide in serum-free medium during 
transfection 48 
3.4 Detection of effects of Glut5 antisense oligonucleotides of breast 
tumor cells-MTT assay 50 
！ 
Antisense Inhibition of Glucose Transporter 5 on Breast Tumor Ccl Is 
3.5 Detection of the antiproliferative effect by trypan blue exclusion 
assay and thymidine incorporation 56 
3.6 Cell cycle analysis and DNA extraction 61 
3.7 Suppression of Glut5 mRNA detected by RT-PCR 66 
3.8 Suppression of translation of GlutS proteins as indicated by Western 
blotting 73 
3.9 Measurement of the fructose and glucose uptake in MCF-7 and MDA 
-MB-231 cells after antisense treatment 76 
3.10 Change of the phosphofmctokinase-1 (PFK-1) activities in MDA-
MB-231 cells 82 
3.11 Measurement of the change in the intracellular pH of the breast 
tumor cells 84 
4 DISCUSSION 89 
4.1 The insights of Glut5 antisense oligonucleotide into cancer therapy.... 89 
4.2 The uptake pattern of GlutS antisense oligonucleotides in breast 
tumor cells 90 
4.3 Stability of antisense oligonucleotide during transfection 92 
4.4 Effects of Glut5 antisense oligonucleotide on MCF-7 and MDA-MB-
231 cells 93 
4.5 Proofs of undergoing antisense action mechanism 95 
4.6 Physiological changes in breast tumor cells after antisense treatment... 97 
5 CONCLUSION 103 
6 References 104 
Antisense Inhibition of Glucose Transporter 5 on Breast Tumor Cells 
Abstract 
In recent years, antisense oligonucleotide therapy has intrigued scientists to 
investigate its application on cancer diseases. Antisense oligonucleotides can be used to 
down-regulate the mRNA expression by annealing to specific and determinable region 
of the target mRNA. Translation of the target gene will then be inhibited. 
Since the metabolic rate of cancer cells was found to be higher than normal cells, 
upset of the metabolic rate might be more adverse to cancer cells. Uptake of substrates 
such as monosaccharides plays an important role in affecting the metabolic rate while 
monosaccharides are mainly transported by glucose transporters. On the other hand, 
glucose transporter 5 (GlutS) is a tissue-specific transporter that can be found on breast 
cancer tissues rather than on normal breast tissues. Therefore, it is interesting to 
investigate whether antisense oligonucleotides against Glut5 mRNA can tackle breast 
cancer. 
In this study, two cell lines, MCF-7 and MDA-MB-231, were used to mimic breast 
cancer tissues at different stages, namely hormone dependent and hormone independent 
stages respectively. Lipofectin, a cationic lipid, was used as a carrier to enhance the 
uptake of the oligonucleotides while the bases were phosphorothioated in order to 
increase their stability. A 15 and a 21 base sequence around the start codon ofGlutS was 
used and the suppression of Glut5 mRNA at different time points was also investigated 
by RT-PCR. Moreover, the reduction in the level of Glut5 mRNA did cause the 
suppression of translation. This resulted in reduction of the Glut5 proteins in both cell 
lines as detected by the Western blot. On the other hand, the ^"^C-fmctose was used to 
investigate its uptake in both cell lines after the treatment of antisense oligonucleotide. 
As expected, the fructose uptake of the antisense treated cells was lower than the sense 
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sequence treated control. It was also found that Glut5 antisense oligonucleotide exerted 
antiproliferative effect on breast tumor cells. Moreover, the antiproliferative effect of 
antisense oligonucleotide seemed to be specific to cells that expressed Glut5 proteins. 
For other tumor cells without Glut5 proteins such as human hepatoma cells (HepG2 
cells), the effect of the oligonucleotide was mainly due to non-specific effect and the 
effect was subtle. 
Since the fructose uptake was reduced after the treatment of antisense 
oligonucleotide, the major metabolic pathway of fructose, the glycolytic pathway, was 
thought to be affected. In MDA-MB-231 cells, the activity of phosphofructokinase 
(PFK), one of the key enzymes in glycolysis, was found to be reduced after antisense 
treatment. This indicated that the rate of glycolysis was inhibited. Moreover, 
intracellular pH change was observed in both cell lines with antisense treatment. There 
was a decrease in the intracellular pH. This may be due to an increase in lactic acid 
production. Further experiments should be done in order to investigate the mechanisms 
undergone and the application of the Glut5 antisense oligonucleotide in animal model 
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1. Introduction 
1.1 Incidence rate of breast cancer in Hong Kong 
The incidence of breast cancer in Hong Kong is increasing. It has become the 
second most common cancer in female (Chow, et al, 1997; Alagaratnam, 1995), 
although the death rate remained steady over the last decade. It is about 10 deaths per 
100,000 females while the age-standardized incidence rate is 34 per 100,000 according 
to the annual report of the Department of Health. However, these numbers do not reflect 
the true incidence of breast cancer because notification of breast cancer in Hong Kong 
is voluntary. The awareness of the seriousness of breast cancer among female is still 
very weak. Moreover, the mean age of the patients in Hong Kong was around 51-56 
years old while the first peak of having breast cancer was between 45-49. According to 
a survey, more than 60% of the patients were postmenopausal women. The estrogen 
receptor status had also been- investigated in some surveys (Alagaratnam, 1982). There 
is a close relationship between the receptor status and responsiveness towards endocrine 
therapy. In the pre- and perimenopausal group, 41% of patients were found to be 
receptor positive on their cancer cells. This figure was lower than the corresponding 
figure for Japanese (57%) and American (59%) women. For the postmenopausal group, 
the proportion of receptor positive patients (56%) was also lower than that of American 
patients but similar to that of the Japanese women (55%). Nevertheless, the incidence 
rate of breast cancer in Hong Kong is much lower than most of the western countries 
but is quite high compared with some of the Asian cities such as Mainland China and 
Japan. Therefore, breast cancer will become a more and more important health care 
issue in Hong Kong in the future years. 
5 
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1.2 Estrogen and breast cancer 
There is a widely accepted model for breast cancer progression (Fig. 1.1). The 
transition from normal to neoplastic epithelium dose not stop with the generation of the 
initial cancer cells (King, 1992; Darbre & King, 1987). Changes will take place 
according to their hormone sensitivity. For the initial stage, breast cancer cells are 
normally hormone dependent that means an absolute requirement of hormone for their 
growth. These hormone dependent cancer cells can then progress to responsive and the 
unresponsive phenotypes. ‘Hormone responsive' means an altered proliferation above a 
basal growth rate exerted by hormone while 'unresponsive' means an unaltered effect 
on growth. The later state was thought to have advantages for the cancer cells to grow 
over the hormone dependent condition. It is because low hormone levels as encountered 
in postmenopausal women do not affect the proliferation of the cancer. 
Estrogen was thought to play an important role in the carcinogenesis of breast 
cancer. Changes of its sensitivity in breast cancer cells could be observed. The 
progression from estrogen dependent to estrogen independent species had been 
demonstrated on nude mice (Clarke et al., 1989). Loss of estrogen receptor, abnormal 
receptor or estrogen resistant development may be the causes. Moreover, the estrogen 
sensitivity was found to have a close association with the effectiveness of the hormone 
therapy such as the usage of tamoxifen. By quantitation of the estrogen receptor in 
specimens, patients can be divided into two main groups: estrogen receptor positive and 
negative groups. Generally, the receptor negative group does not respond well under 
hormone therapy. Moreover, estrogen receptor negative cancer cells were thought to be 
more invasive. A survey had found that up to 24% of metastases were with their 
estrogen receptors lost (Kuukasjarvi et al., 1996). There was also a better disease-free 
6 
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survival time for patients with estrogen receptors compared with those with receptor 
negative tumors. Although the hormone therapy is a promising strategy for treating and 
preventing breast cancer, it seems that the responsiveness towards this therapy in 
estrogen receptor negative tumors was poor and antiestrogen resistant species could also 
be observed. Moreover, side effects such as increased risk of endometrial cancer and 
osteoporosis have been reported (Peters-Engl et al., 1999). 
Normal ^ Hormone Dependent Cancer 
，r 
^ Hormone Responsive Cancer 
y + 
• Hormone Unresponsive Cancer 
Fig. 1.1 Pathways of progression of normal hormone sensitive cells to unresponsive 
cancer cells in breast cancer (Adapted from King, 1992). 
1.3 The relation between glucose transporters and breast cancer 
Six mammalian glucose transporters have been identified so far. These proteins are 
named Glut 1-5 and Glut? while Glut6 is a pseudogene that cannot be detected in protein 
level. All of these proteins share a common structural motif that possess 12 
_7 
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transmembrane segments with their amino and carboxyl termini located in the cytosol 
(Fig 1.2). There are large loops between transmembrane segments 6 and 7 containing 67 
amino acids in Glut2-5 (Gould & Holman, 1993). Such loop divides the transporter into 
two halves, the N-terminal domain and the C-terminal domain. Asparagine and 
threonine in segment 8 may be involved in the hydrogen bonding required for hexose 
movement through the channel and release at the inner surface. At the level of tertiary 
structure, the segment 12 seems to provide an aqueous channel that penetrates the cell 
membrane (McGowan et al., 1995). 
All of the facilitative glucose transporters are expressed in a tissue- and cell-
specific manner with distinct kinetic and regulatory properties. For example, Glutl can 
virtually be found in all tissues and are especially abundant in erythrocytes and brain. 
Glut2 are present in liver, pancreatic islet cells, kidney and small intestine while Glut3 
are abundant in brain. Glut4 are restricted to adipose and skeletal tissues. Glut5 can be 
found in small intestine and sperm cells while Glut? are restricted to microsomes of 
hepatocytes. They exhibit different affinity for glucose and other monosaccharides. 
Generally, cancer cells have a higher metabolic rate than normal cells. This may be 
due to their high proliferation rate (Grover et al,, 1998). Glucose utilization was found 
to increase in many tumors (Dills, 1993; Au et al., 1997). Since glucose transporters 
mediate the major route of entry of glucose, overexpression of a particular type of 
glucose transporter can usually be found. For example, Glutl expression was found to 
increase in breast cancer with higher grade and proliferative activity (Younes et al., 
1995). This phenomenon can provide some diagnostic insights. The high rate of glucose 
uptake in cancer cells is sometime used in the clinic to localize tumors in patients and to 
assess tumor metabolism and response to therapy by positron emission tomography 
(PET) scanning with ['^Fjfluorodeoxyglucose (Wahl et al” 1992). There is also a close 
relationship between malignant transformation and expression of glucose transporters. 
- 8 
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Transforming oncogenes can regulate glucose transport in tumor cells. Usually, 
oncogene-transformed cells have an increase in glucose transport and so the energy 
utilization. It was found that ^rc-transformed chicken embryo fibroblasts and raf-\ 
transformed 3T3-L1 fibroblasts had an elevated glucose transport than the native one 
(Fingar & Bimbaum, 1994; White et al., 1991). This change in glucose uptake was 
achieved by increasing the expression of a particular glucose transporter, such as Glutl, 
a decrease in the degradation rate of this protein or a decrease in Km by structural 
modification in glucose transporters (Merrall et al., 1993; Ahmed & Berridge, 1998). 
Therefore, it was thought that oncogene can activate glucose transport in tumor cells so 
as to maintain the high metabolic and proliferation rate. On the other hand, suppression 
of the glucose uptake would be harmful to tumor cells. Many anti-cancer drugs included 
methotrexate and tumor necrosis factor-a can interfere the glucose transport (Fung et al, 
1985; Chan et al., 1983). The antimetabolite 2-deoxy-D-glucose which downregulated 
the Glutl and inhibited glycolysis was toxic to cancer cell lines (Bentley et al., 1996). It 
was also found that glucose deprivation could induce cytotoxicity in breast carcinoma 
cells (Lee et al., 1998). All these evidences suggested that alteration in glucose transport 
and glucose utilization would be adverse to cancer cells. 
Facilitative glucose transporters are expressed in a tissue-specific manner. Among 
the members, Glut5 is the most divergent member, sharing only 40% identity with the 
other members of the glucose transporter family. GlutS can be located on the brush 
border membrane of small intestinal enterocytes and spermatozoa. It is conceivable that 
both the N-terminal half and the intracellular C-terminal region are mandatory for the 
transport of fructose (Inukai et a!., 1995). Glut5 was thought to be a fructose transporter 
with a Km varied from 6 mM to lOmM (Miyamoto et al, 1994; Burant et al” 1992) as 
determined by different laboratories. This affinity for fructose is approximately ten 
times higher than Glut2 and the uptake of fructose is not inhibited by 2-deoxy-D-
9 
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glucose and cytochalasin B. Interestingly, Glut5 is highly expressed in vivo in human 
breast cancer but is absent in normal human breast tissue (Zamora-Leon et al., 1996). 
These findings indicate that breast cancer cells have a specialized capacity to transport 
fructose which is a rare metabolic substrate for most tissues. The reason is still not clear 
but it is speculated that fructose prefers glycolysis and may be a good substrate for 
energy generation in malignant cells because glycolysis is the principal metabolic 
pathway for energy production. 
— — ••="， 
O HydrophoWc CHO • 眺 r 
\ J \ �l-ys，Arg 
' ^ C O O H 
Fig. 1.2 The predicted topology of Glu t l . 
The 12 predicted transmembrane helices are numbered 1 — 12. This is the general 
structure for glucose transporters (Adapted from Mueckler, 1994). 
1.4 Antisense oligonucleotide 
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progressed significantly over the past 10-15 years. The theoretical basis of antisense 
was first proposed in 1967. Later, some scientists determined that chemical modification 
* of the native molecule would result in protection from nucleases. The realization of its 
potential in treatment of different diseases did not occur until 1978 when in vitro 
experiments were able to demonstrate sequence-specific inhibition of the expression of 
Rous sarcoma vims (Stephenson & Zamecnik, 1978). Antisense RNA has been proven 
to be a powerful tool for manipulation of gene expression. Down-regulation of gene 
expression by antisense RNA was first recognized as a naturally occurring mechanism 
in prokaryotes. Processes such as plasmid replication, transposition and phage 
reproduction all share the common feature of interaction of a sense and a short antisense 
transcript. Naturally occurring antisense genes in eukaryotes have also been identified 
in recent years. The transcripts containing complementary sequences to known genes 
including mouse dihydrofolate reductase, chicken myosin heavy chain and Drosophila 
dopadecarboxylase (van der Krol et al., 1988). 
The attractiveness of antisense oligonucleotides being & novel therapeutics is their 
abilities to target mRNA or other RNAs in a sequence-specific manner. Therefore, they 
can achieve a highly specific manipulation of gene expression. Moreover, it has a huge 
potential on clinical application because antisense' oligonucleotides not only can 
suppress the expression of a gene causing undesirable J^henotype but also can be used to 
investigate the function of a gene or interfere with viral infection. 
1.5 Action mechanisms of antisense oligonucleotide 
Antisense oligonucleotides refer to short, single-stranded DNA or RNA that 
contain sequences complementary to a particular mRNA. Through Watson and Crick 
base pairing, a duplex would be formed and interfered the expression of the mRNA. 
y 
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There are several action mechanisms proposed in achieving gene manipulation (Fig 1.3). 
First, direct binding of the antisense oligonucleotide to its mRNA target, thereby 
‘ sterically inhibiting the translation by translational machine. For example, the binding 
of antisense oligonucleotide on the start codon of mRNA may hinder the binding of 
large ribosome unit on the mRNA. Another mechanism implicates that attachment to 
the 5' capping site of mRNA inhibits the binding of translational factors. Furthermore, 
forming of a DNA-RNA duplex will result in activation of RNase H. In turn, this will 
lead to degradation of the RNA strand and release of the antisense oligonucleotide to 
continue its action. As a result, the mRNA is eliminated and the protein level would be 
reduced (Curcio et ai, 1997). It was found that native oligonucleotide and some of the 
modified oligonucleotides such as phosphorothioation can achieve through this means. 
Moreover, oligonucleotides can enter nucleus and interact directly with the gene of 
interest. Some of them are designed to be capable of forming triplex with the target gene. 
These oligonucleotides bind to the genes which contain a purine-rich strand of DNA via 
Hoogsten hydrogen bonds between the third-strand nucleotide and their complement in 
the purine-rich strand. The third strand may contain either polypurines or 
polypyrimidines. In consequence, the formation of a triple helix would prevent 
unwinding of the DNA strands and so the DNA-polymerase mediated transcription. 
Thus, the normal functions and expression of the genes are hindered. However, the 
choices of the target genes are limited in this approach because it is not dependent on 
normal Waston-Crick hybridization. Antisense oligonucleotides can also disrupt protein 
synthesis by interference with proper mRNA splicing through binding to splice donor or 
acceptor sites of the pre-mRNA (Mercatante & Kole, 2000). Selective inhibition of a 
particular splice variant can be achieved. Oligonucleotides can also be used as aptamers 
to inhibit proteins and other molecules directly and specifically (Bishop et aL, 1996). 
However, this application is rare and difficult. 
12 
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Fig. 1.3 Potential action mechanisms of antisense oligonucleotides. 
Antisense oligomers might sterically inhibit replication, transcription or translation, 
recruit RNase H to target RNA. Aptamer oligonucleotides bind proteins directly through 
a specific sequence or duplex oligonucleotides might sequester proteins (Adapted from 
Miller and Das, 1998). 
1.6 Modification of the oligonucleotide 
Conventional oligonucleotides are substrates for nucleases. The half-life of an 
13 
Antisense Inhibition of Glucose Transporter 5 on Breast Tumor Cells 
oligonucleotide varies from minutes to several tens of hours as determined in different 
laboratories. It was found that the major activity responsible for degradation in fetal calf 
serum was 3’ exonuclease (Toulme, 1992). Since stability is one of the important 
criteria for the success of an oligonucleotide, modification of the molecule is commonly 
introduced to overcome the nuclease activities. There are numerous chemical 
modifications applied to make the oligonucleotide more nuclease resistant (Fig 1.4). 
Among them, phosphorothioates (S-olio) are probably the most widely used in which 
one of the non-bridging oxygen in the phosphodiester bond is replaced by a sulfur atom. 
The negative charge of the oligonucleotide remain unchanged. Although the binding 
affinity is lower relative to the native phosphodiester bond, this can be overcome by 
adjusting the base composition (Cohen, 1993). Other modifications such as 
methylphosphonate, phosphoramidate, phosphoroselenoate or a—isomer configuration 
can also reduce the metabolic rate of the oligonucleotide. Unlike phosphorothioate 
modification, these modifications cannot trigger the activity of RNase H to breakdown 
the RNA-DNA duplex. Therefore, they can only exert their effects through steric 
hindrance. In recent studies, a novel biopolymer draws new insight into oligonucleotide 
synthesis. The original sugar-phosphate backbone of the DNA is replaced by a 
polyamide backbone to form a peptide nucleic acid (PNA). Individual nucleobases are 
linked to the achiral neutral peptide backbone with a similar interbase distance as 
natural DNA (Fig 1.5). This structure is resistant to both nuclease and protease. PNA 
also has a high affinity and adequate flexibility to bind to both DNA and RNA. It has 
high biological stability and is penetrable to cells (Bakhtiar, 1998; Puschl et al., 1998). 
PNA has been proven to inhibit inducible nitric oxide synthase in mouse macrophages 
although the usage of PNA is still in preliminary stage (Scarfi et al” 1999). 
14 
Antisense Inhibition of Glucose Transporter 5 on Breast Tumor Cells 
D O S 
R〇——P——OR, RO——P——OR' RO——P OR' 
S- Se- S-
I II III 
o s 
R O — P — O R ' R O — P — O R ' 
CH3 CH3 
IV V 
Fig. 1.4 The structure of different modifications on the phosphodiester bond. 
I, Phosphorothioate; II, phosphoroselenoate; III， phosphorodithioate; IV, 
methylphosphonate; V, methylphosphonothioate. 
H O 
r v ^ 
\ B: nucleobase 
N H 
々 
� f B 
H 2 N 
Fig. 1.5 The structure of peptide nucleic acids. 
The normal sugar-phosphate backbone is replaced by N(2-aminoethyl)glycine 
backbone. 
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Besides nuclease resistance, some modifications aim to enhance the effects of 
antisense oligonucleotides on inhibition of gene expression. For example, active groups 
are coupled to the oligomers that can cause irreversible damages to the target sequences. 
Alkylating reagents are one kind of them which can introduce sequence-specific 
alkylation of nucleic acids. Other coupling such as antibody conjugation can 
specifically deliver the antisense oligomer to a particular target cell. In this study, 
phosphorothioate oligomers were used because it is common, easy to synthesize and 
cost effective. 
1.7 Length 
Theoretically, the minimal length of an antisense oligonucleotide to be sufficiently 
unique to its target sequence is 15. Although the lengthening of the sequence would 
increase the uniqueness, the chance of non-sequence specific binding is also increased. 
It is also more expensive to synthesize longer oligonucleotide. Commonly used lengths 
are 15-25 bases long. Within this range, both the sufficiency of picking out a unique 
sequence from the human genome and cost effectiveness can be attainable. This size of 
antisense oligomer can successfully discriminate between two gene products differed by 
a single base mutation. Both 15 and 21 bases long oligomers would be used in this study 
and some of their effects would be compared. 
1.8 Sequence selection of the antisense oligonucleotide 
The criteria for choosing the best sequence for antisense activity against a target 
mRNA is still largely an empirical exercise. Not all the regions among the same mRNA 
16 
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are equally accessible for antisense oligonucleotide. Moreover, hybridization of 
antisense oligonucleotides with different regions of the mRNA leads to different action 
mechanisms in order to carry out their effects. For example, antisense against the start 
codon or the 5' cap region of the mRNA can act through steric hindrance and prevent 
ribosomes from binding or scanning the message. For oligonucleotides complementary 
to the coding regions or the 3’ site of the mRNA are not inhibitory unless they can 
trigger the activity of RNase H. The degree of effectiveness is different compared with 
different target region along the mRNA. It is not necessarily true that antisense 
oligonucleotide against the start codon should be more effective than that against the 3’ 
untranslated region (Monia et al., 1996). On the other hand, the affinity of antisense 
oligonucleotide towards its target site should also be considered. The most empirical 
consideration is to adjust the GC content of the antisense oligomer. Theoretically, higher 
GC content will contribute to higher affinity for the target but a high percentage of these 
nucleotides, such as four contiguous G residues, could result in the formation of 
secondary or tertiary structures within the oligonucleotide (Miller & Das, 1998). 
Nevertheless, secondary structure of the antisense oligonucleotide may be used as a 
protective modification in some cases. A novel ribbon-type antisense oligonucleotide 
which could avoid exonuclease activities was studied in recent year (Moon et al., 2000). 
Besides, the target RNA usually has its own secondary or tertiary structure. Under 
physiological condition, the target RNA may fold into specific structures, such as 
hairpin loop, without extended single-stranded regions. These structure will in turn 
affect the binding affinity and rate of oligonucleotide hybridization. The antisense 
oligonucleotide may also need to compete with proteins that bind to the same site on the 
message (Petyuk et al, 1999; Vickers et al., 2000). One strategy of identifying the best 
sequence for the antisense oligonucleotide adopts a 'gene-walk' approach around a 
known structure so as to determine the binding site with the highest in vitro affinity for 
17 
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the target (Lima et al” 1997). The main drawback of this approach is the inconsistency 
of the results and the work is laborious. Uniqueness of the selected sequence is also 
important. Homology of the sequence among the genome should be minimized in order 
to prevent any mismatched binding. The homology of the oligomer can be checked 
through a program 'Blast' against the databases in GeneBank. 
1.9 Delivery means in antisense oligonucleotide 
The efficacy of delivery of antisense oligonucleotides is critical to the success of 
their applications. To enhance the uptake efficacy of antisense oligonucleotide, different 
delivery methods were introduced. For examples, microinjection of oligonucleotides 
into the target cells permit the determination of the quantity of oligonucleotides actually 
present in the cells (Leonetti & Leserman, 1993). By this means, the injected oligomers 
would rapidly accumulate in the nucleus (Leonetti et al., 1991). Electroporation is 
another potential method for delivery. It is a phenomenon in which lipid bilayers 
exposed to high intensity electric field pulses are temporarily destabilized and 
permeabilized (Regnier et al., 1999). In this study, liposome, one of the most common 
delivery methods was used. Liposomes are closed spherical structures of diameter 
ranging from between 50 nm and a few jam (Maurer et al” 1999). They can encapsulate 
both aqueous and lipophilic drugs because they possess both lipophilic membrane and 
aqueous cavity. Moreover, these vesicles are biodegradable under physiological 
conditions and will not interfere with the function of the oligonucleotides. Modification 
of liposome surface is also a common practice to improve the oligonucleotide loading. 
For instance, polyethylene glycol was coated with liposome surface in order to increase 
particle stability and reduce the interaction with biological macromolecules and the 
aggregation. In our study, cationic liposomes were used. These liposomes were 
18 
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composed of a univalent cationic lipid and the neutral helper lipid. By X-ray diffraction, 
it was proposed that the DNA was coated by cationic lipid monolayers and arranged on 
a two-dimensional hexagonal lattice (Fig 1.6). The structure shielded the 
oligodeoxynucleotides and aided in the entry of cells. 
a * 
Fig 1.6 Two distinct pathways in formation of columnar inverted hexagonal lattice. 
(A) The cationic lipid is cylindrically shaped whereas neutral lipid is conelike, leading 
to the negative curvature. (B) Cosurfactant hexanol is added with the neutral lipid. The 
dark rings inside the column are oligodeoxynucleotides (Adapted and modifed from 
Koltover et ai, 1998). 
1.10 The therapeutic role of antisense oligonucleotide 
The potential of antisense oligonucleotide in cancer therapy has been widely 
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studied in the last decade. Antisense oligonucleotides were designed to inhibit the 
expression of a particular protein for which it is usually overexpressed and play a 
relevant role in neoplastic transformation, conveying mitogenic signals of different 
growth factors or being an oncogene. For examples, anti-gastrin oligonucleotide was 
applied to suppress the growth of pancreatic cancer while anti-MDRl oligonucleotide 
could be used to block the P-glycoprotein synthesis and so the anti-tumor drug efflux 
activity would be inhibited (Alahari et al., 1998; Smith et al., 1999). In breast cancer, 
the therapeutic role of using antisense oligonucleotides had also been accessed. The 
oncogenes c-myc and erbB-2 were the common targets in treating breast cancer because 
mutant form or overexpression of these genes can be found in many breast cancer cases 
(Watson et al., 1991; Vaughn et al., 1996). Moreover, the suppression of protein kinase 
A or DNA polymerase a by antisense mechanism was found to be valid (Alama et al., 
1993; Tortora et al., 1999) in suppression of the growth of breast cancer cells. 
The initial success in the first generation of oligonucleotides in cell culture 
encouraged a rapid development to in vivo models. The pharmacokinetic and 
metabolism of antisense oligonucleotides has been widely studied. These studies 
suggested that the organs of the reticuloendothelial system such as liver, kidney and 
spleen may be the major sites of accumulation of oligonucleotides (Raynaud et al., 1997; 
Zhang et al., 1995). Different ways of administration including intratumoral, 
subcutaneous and intravenous injection, electroporation and even oral intake had been 
investigated (Baba et al., 2000; Wang et al., 1999). The dose of oligonucleotide and the 
dosing regimens that appeared to be successful in these pre-clinical studies seemed 
variable in different experiments. Recently, the usage of antisense oligonucleotide has 
been applied in clinical trial. Antisense oligonucleotide targeted to BCL-2 mRNA was 
administrated subcutaneously to patients with non-Hodgkin lymphoma (Webb et al., 
1997). Reduction of tumor size was observed. Although there was promising evidence 
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in clinical trial, there were tremendous problems waiting to be solved. The safety and 
toxicity could not be guaranteed in in vivo studies. Inflammation and haematological 
toxic effects could be resulted. Moreover, non-specific effects as observed in cell culture, 
the need of efficient delivery to the target site and the issue of high costs in 
manufacturing large quantities of oligonucleotides all hinder the future of antisense 
oligonucleotides being a novel therapeutic agent. 
1.11 Objective of the project 
In my project, antisense oligonucleotide is used to act against the Glut5 expression. 
Since the facilitate glucose transporters play an essential role in mediating nutrients' 
transport into tumor cells, the reduction of these transporters' expression might result in 
reduction in nutrient supply. As a consequence, the metabolic rate of the tumor cells 
would be affected and so the active growth of the tumor cells may be suppressed. 
Another important reason for choosing Glut5 as the target is attributed to the highly 
specific expression of Glut5. Glut5 was found to only localize in breast carcinoma but is 
not detected in normal mammary epithelial cells (Fig 1.7). Accompanying with the 
tissue specific expression in spermatocytes and intestinal cells, the effect of anti-Glut5 
oligonucleotide would be highly localized on those neoplastic tissues in breast but 
prevent normal tissues surrounding from being affected. In addition, both estrogen-
receptor positive and negative breast tumor cells possess Glut5. That means different 
stages of breast carcinoma can be effective if the action of anti-Glut5 oligonucleotide is 
sound. It is because the suppression of only one kind of cell population would lead to 
the continuous growth of another cell population. It was found that there was a 
paracrine stimulation of MCF-7 cells by the co-cultured MDA-MB-231 cells. This 
stimulation was found to counter-act the antiproliferative effects on MCF-7 cells 
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treatment. Moreover, it was speculated that the expression of relative rare Glut5 on 
breast carcinoma should have the importance or advantages for cancer growth. 
Suppression ofGlutS, therefore, has its potential on tackling breast cancer. 
• • • 
• • 
Fig 1.7 Localization of glucose transporter 5 on normal mammary tissues (A) and 
human neoplastic tissues (B and C ) 
The Gluts was stained in dark blue (Adapted from Zamora-Leon et al., 1996). 
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2. Materials and Methods 
2.1 Materials 
Phosphate buffered saline (PBS) was prepared by mixing 136mM NaCl, 2.7mM KCl， 
l.SmM KH2PO4 and 8mM Na2P04. All the chemicals were dissolved in double distilled 
water (ddHsO). The pH of PBS was adjusted to 7.4 and was autoclaved to make it 
sterile. 
Hank's balanced salt solution (HBSS) was prepared by mixing 5.33 mM KCl, 0.44 
mM KH2PO4, 4 mM NaHCO�，138 mM NaCl, 0.3 mM Na2HP04 and 5.6 mM glucose. 
All the chemicals were dissolved in ddHsO and the pH of the solution was adjusted to 
7.4. 
Tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT, Sigma) was dissolved in PBS at concentration of 5 mg/ml. The solution was 
filtered by a 0.22)Lim Millipore filter. 
Roswell Park Memorial Institute tissue culture medium 1640 (RPMI1640 medium) 
was used for cell culture. Each pack of the powder of RPMI 1640 medium containing 
Phenol red, L-glutamine and 0.5 mM HEPES was dissolved in 1 liter of dHsO. The 
medium was supplemented with 2 g of NaHCO�. The pH of the medium was adjusted to 
7.2-7.3. Finally, medium was filtered by 0.22 i^m bottle-top filter (Millipore). The 
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and 10% FBS (v/v). All RPMI 1640 powder, fetal bovine serum and penicillin-
streptomycin (10,000 U/ml) were bought from Gibco BRL Life technologies. 
Tris-EDTA (TE) buffer was prepared by mixing 10 mM Tris-Cl and ImM EDTA. The 
solution was adjusted to pH 7.4. 
Tris-acetate (TAE) buffer was first prepared as a 5OX concentrated stock solution (per 
liter). It contained 242 g Tris base, 57.1 ml glacial acetic acid and 100 ml 0.5 M EDTA 
(pH 8.0). 
Tirs-borate (TBE) buffer was prepared as a 5x concentrated stock solution (per liter). 
It was composed of 54 g Tris base, 27.5 g boric acid and 20 ml 0.5 M EDTA (pH 8.0). 
Lysis buffer was prepared as following: 
1% SDS 
1 mM Sodium Meta-Vanadate 
10 mM Tris buffer (pH 7.4) 
21 jig/ml Aprotinin 
5 |ig/ml Leupeptin 
5 mM Magnesium Chloride 
1 mM PMSF 
All these constituent were dissolved in PBS and stored at room temperature. 
Cell cultures 
Human breast cancer cell lines MCF-7 and MDA-MB-231 were purchased from 
American Type Culture Collection (ATCC). They were grown in RPMI-1640 medium 
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supplemented with 10% fetal calf serum, 500 units penicillin and streptomycin and 
buffered with 25 mM NaHCO� in a humidified atmosphere of 5% C O � at 37 
Oligodeoxynucleotides 
Sense and antisense phosphorothioate oligodeoxynucleotide (ODN) molecules against 
Glut5, both 15 and 21 base pairs, were designed in our laboratory and synthesized by 
Gibco BRL or Golden Pacific Ltd. The coupling efficiency stated was 98 % and the 
oligonucleotide was purified by cartridges or desalted. The commercial 
oligodeoxynucleotides were reconstituted in sterile PBS. The solution was then filtered 
with an acetate 0.22|Lim filter and stored at -20 
Fluorescein-5-isothiocyanate (FITC) labeled phosphorothioate 
oligodeoxynucleotides (ODN), 15 or 21 base pairs, were synthesized by Gibco BRL. 
Fluorescein was covalently bound to ODNs at 5' end. The coupling efficiency stated 
was 98 % and the oligonucleotide was purified by cartridges. The labeled ODN was 
phophorothioated at each base. The commercial oligodeoxynucleotides were 
reconstituted in sterile PBS. The solution was then filtered with an acetate 0.22|Lim filter 
and stored at -20 
BCECF (2',7'-bis-[2-carboxyethyl]-5-(and-6)-carboxyfluorescein) AM (acetomethyl) 
ester was purchased from Molecular Probes. The powder was reconstituted on reagent-
grade, anhydrous dimethylsulfoxide (DMSO) to a final concentration 5 mM. The stock 
solution was aliquoted into several Eppendorf tubes and stored at —20�C. 
SYBR Green I nucleic acid gel stain was purchased from Bio-Gene Technology Ltd. 
The stock was frozen at -20 desiccated and protected from light. The stock was 
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diluted 10,000-fold in TE buffer. The staining reagent could be stored and protected 
from light at 4 °C for several weeks. 
Nigericin (Molecular Probes) was dissolved in absolute ethanol to a final concentration 
5 mM. The stock solution was stored in 4 
Tamoxifen was purchased from Sigma. The powder was reconstituted in 70 % ethanol 
to a concentration 10 mM. The stock solution was stored at 4 The working solution 
was diluted with RPMI 1640 to the final concentration. 
Propidium iodide (PI) and RNase A were purchased from Sigma. PI was reconstituted 
in PBS (2mg/ml) while RNase A was dissolved in TE buffer (pH 7.4). 
Trizol Reagent, Lipofectin and SuperScript Preamplification System were 
purchased from Gibco BRL while [^ "^ C] Fructose and 2-Deoxy-D-[ 1 -^H] glucose were 
purchased from Amersham. 
2.2 Methods 
Oligonucleotide sequence design 
The sequence of antisense Glut5 was selected to be complementary to human 
glucose transporter 5 cDNA sequence around the start codon region started at base 70. 
For 15 base-pair antisense, the sequence was : 5'- TTG CTC CAT GCT TGC -3，. Six 
further bases (ATC CTG) were added to the 5' end if a 21 base length antisense was 
chosen. The sequence of sense control for Glut-5 was the same as the start codon region 
of human glucose transporter 5 cDNA sequence. The 5' to 3' sequence was: 5'- GCA 
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AGC ATG GAG CAA -3’(CAG GAT if in 21 base length species). These selected 
sequences were checked against their specificity by using the program ‘Blast，against 
the non-redundant database in Genbank. The web site used was: 
http://www.nebi.nlm.nih.gov. All the ODN was also phophorothioated at each base. 
Thus, one of the non-bridging oxygen in the phosphodiester bond was replaced by a 
sulfur atom. This modification could enhance the stability in culture medium. 
Transfection 
Lipofectin was used as a carrier to enhance the uptake of the oligonucleotides. 
Firstly, lipofectin in the same amount (w/w 1:1) as the oligonucleotide was added to the 
serum free RPMI medium for 45 minutes at room temperature. After then, 
oligonucleotide was added to the mixture for further 15 minutes and the DNA-lipofectin 
complex was added directly to the cells. After 15 hr transfection in a humidified 
atmosphere of 5% CO2 at 37 the serum-free medium was removed and replaced 
with fresh complete medium. The cells were further incubated at 37 5% CO2 until 
another assay was carried out. 
MTT [Tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide； 
assay 
2x104 cells per well were seeded on a 96-well plate in 100 i^l medium. After 24 hr 
incubation, transfection was carried out. At the appropriate time, the medium of each 
well was removed. Each well was then washed with PBS once. Volume of 50 |al of a 5 
mg/ml solution of MTT was added into each well and the plate was incubated at 3 7 � C 
for 2 hr. After then, 150 )li1 of D M S O was added and incubated at room temperature for 
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further 30 min. The plate was shaken for a while and the optical density of each well 
was measured at 540 nm by an ELISA plate reader (BIO-RAD). 
Trypan blue exclusion assay 
15 cell suspension was aliquoted and mixed with equal volume of 0.4% trypan 
blue solution. The mixture was stood for 3 min at room temperature and 10 |il was 
transferred to the hemacytometer. Only viable cells (unstained cells) were counted. Each 
square of the hemacytometer represented a total volume of 0.1 mm^. Since 1 cm^ was 
equivalent to approximately 1 ml, the subsequent cell concentration per ml was 
calculated as follows: 
Cells per ml = the average count per square x dilution factor x lO"^  
Thymidine incorporation 
For 24-well plate, 6x10"^  cells per well were seeded in 400 |il medium. After 
appropriate treatment, the medium was discarded and 0.5 |LiCi [methyl-^H] thymidine 
(Amersham) in 400 culture medium was added to each well. The plate was then 
incubated at 37 °C for 3 hr. The medium was then removed and the well was washed 
with 1 ml PBS once. One ml 10% trichloroacetic acid (TCA) was then added and the 
plate was stood for 1 hr at room temperature. The TCA was discarded and followed by 
washing in PBS twice. Volume of 200 |li1 of 0.1% SDS and 50 jul of IN NaOH were 
added to lyse the cells. The lysate was finally pipetted up and down and mixed with 1.5 
ml scintillant in scintillation vial for counting. 5 t^l of the cell lysate was used to 
perform BCA method so as to evaluate the protein amounts. 
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Primer design 
A 33 bases sequence of the end of Glut5 mRNA was chosen to be the primers used 
in PGR. The forward primer sequence was : 5' -TAG GGC A A G CTT CTG A A G TGT 
ACC CGG A A A AGG - 3 ' while the reverse primer sequence was : 5’ - T A G GGC 
GCG GCC GCG A A A AGT GAT CAG GTT CAT -3 , . For the glyceraldehyde-3-
phosphate dehydrogenase mRNA, a 20 bases primer was chosen. The forward primer 
sequence was : 5' —ACC AC A GTC CAT GCC ATC AC —3’ while the reverse primer 
sequence was : 5' -TCC ACC ACC CTG TTG CTG TA - 3 ' . These sequences were 
checked by the 'Blast' program o f N C B I for homology. 
Total RNA extraction 
6x10^ cells per well in 800 jul were seeded in 6-well plate. After transfection and 
recovery, medium from the 6-well plate was removed and 0.8ml TRIzol Reagent was 
added to each well in order to lyse cells directly. The lysate was pipetted up and down 
and transferred to a new eppendorf tube. Chloroform at a volume of 0.4 ml was then 
added and the sample was shaken vigorously for at least 15 seconds. The sample was 
centrifuged at 13,600 x g for 15 minutes at 4 After centrifugation, the upper aqueous 
layer was transferred to a new eppendorf. RNA was precipitated from the aqueous 
phase by adding 0.4 ml isopropanol. The sample was stored at —20 for 20-30 minutes 
and centrifuged at 13,600 x g for 15 minutes at 4 The supernatant was removed and 
the pellet was washed with 75% ethanol. After then, the RNA pellet was dried briefly 
and dissolved in 20 jiil DEPC-water. The RNA sample was stored at -70 for not 
longer than a month. 
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RT-PCR 
3-4 [ig of the total RNA was used to synthesize the first strand cDNA. The 
procedures were indicated in the instruction manual of the SuperScript Preamplification 
System. The first strand cDNA was stored under -20 .For PCR, the reagents were 
added as indicated below: 
5 [i\ lOX PCR buffer 
4 1^1 5mM deoxynucleotide (dNTP) 
3 [xl forward primer 
3 reverse primer 
2 1^1 first strand cDNA 
33 (！即 
The reaction mixture was then undergone PCR in a PCR machine (BioRad). The 
program was stated as below: 
9 4 � C f o r 4 m i n 
94 oc for 1 min ” 
25cycles for GAPDH or 5 2 � C for 1 min 30 sec > , SOcycles for GlutS 
7 2 � C for 1 min 30 sec ) 
72 for 15 min 
4 for overnight 
The PCR products were then electrophoresed in a 1 % agarose gel and stained with 
ethidium bromide. The samples were stored at —20�C. 
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Western blotting 
Treated cells were trypsinized and washed with PBS twice. Lysis buffer at volume 
of 80 jul was added, mixed well and stood in ice bath for 30 min. The samples were then 
boiled for 10 min. The protein content of each sample was estimated by BCA protein 
assay. 20-25 |ag samples were used to run sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE, 4.5% stacking gel and 8% running gel). The proteins were 
then transferred to a polyvinylidene fluoride (PVDF) microporous membrane by a semi-
dry transfer system (BioRad). The membrane was blocked in 10% non-fat milk (in 
TBS-T) and stored at 4 overnight. The membrane was incubated in a dilution 
1.5:2000 (in TBS-T) of monoclonal rabbit antibody produced against human Glut 5. 
After 1 hr, the membrane was washed with TBS-T for three times and anti-rabbit IgG 
antibody (1.5:2000 dilution in TBS-T) conjugated with horseradish peroxidase (Santa 
Cruz Biotechnology) was then added for further 1 hr. Enhanced chemiluminescence 
(ECL) detection reagents (Amersham) were used and the emitting signal was detected 
by exposure to autoradiography film (Kodak). The bands were quantified by using 
densitometer (Molecular Dynamics). 
Flow cytometry 
Flow cytometry (FCM) could be used in association with a wide range of 
fluorescent probes in order to measure different cellular parameters. Those cells pulsed 
with FITC-oligonucleotide were trypsinized and washed with PBS twice. After then, the 
cells were resuspended in PBS and were analyzed by ‘Lysys 11，program (Becton 
Dickinson). The population of cells was determined by forward scatter (FSC) light and 
side scatter (SSC) light while the signal of FITC was collected at channel FL-1 (green 
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fluorescence). 
Cell cycle analysis 
Cells (�1x106) in a 6-well plate were washed with PBS once. The cells were 
trypsinized and resuspended in fresh medium. The suspension was then centrifuged at 
300 X g for 5 min and resuspended in PBS. The cells were washed twice and 1.5 ml ice-
cold 70% ethanol was added. The mixture was vortex and stood at 4 for overnight. 
After then, the suspension was centrifuged at 300 x g for 5 min and the cell pellet was 
resuspended in 800 |li1 PBS, 100 |li1 RNase A (Img/ml) and 20 jul propidium iodide (PI, 
2mg/ml). The mixture was incubated at 37 for 30 min and analyzed by FACsort flow 
cytometer (Becton Dickinson). ‘Lysys 11，program was used. The cell population was 
scanned by forward scatter (FSC) light and side scatter (SSC) light which reflected the 
size and granularity of a cell respectively. Different phases of the cell cycle were 
assayed by collecting the signal at channel FL2-A. The percentage of the cell population 
at a particular phase was estimated by the program ‘Cell-fit’. 
Glucose and fructose uptake assay 
6x10^ cells/well was seeded in 6-well plate. After 18-24hr incubation, 2|liM of 
oligo: lipofectin in 500)^ 1 serum medium was added to each well for 15hr at 37 
Serum-free medium was then replaced by fresh complete medium. At appropriate time, 
the medium was removed and the cells were washed with 0.5ml PBS once. O.lmM 2-
deoxy-glucose and 0.5 |LiCi 2-deoxy-[l-^H] glucose (or O.lmM fructose and 0.5 |iCi 
i4C-fmctose for fructose uptake assay, both purchased from Amersham) in 1ml PBS 
was added to each well for 15 min at 37 The PBS was discarded and each well was 
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washed with 10 mM deoxy-glucose or 10 mM fructose dissolved in normal saline twice. 
After then, 400 |al 0.1% SDS was added. Volume of 10 \x\ was used for protein content 
determination and the rest was added with 1.5 ml scintillant for scintillation counting. 
Measurement of intracellular pH change by loading cells with BCECF (2,,7,-bis-
[2-carboxyethyl] -5- [and-6]-carboxyfluorescein) 
An aliquot of 5mM BCECF AM ester stock solution was diluted to 2 i^M in 
Hanks' buffered salt solution (HBSS). Medium from a 24 well plate with viable cells 
(SxlOVwell) was removed. Each well was washed with PBS once. Volume of 200 fil of 
the BCECF solution was added to each well and incubated at 37 °C for 20 min. After 
then, the cells were trypsinized and resuspended in fresh medium. The suspension was 
added to an Eppendorf tube and centrifuged at 300 x g for 5 min. The cells were washed 
in PBS twice. At last, the cells were resuspended in 1 ml HBSS. Each sample was 
placed into a quartz fluorometry cuvette at a final volume of 2 ml. During the course of 
the experiment, the solutions were constantly stirred using a 7mm x 2mm magnetic stir 
bar. Excitation and emission spectra were collected using a luminescence 
spectrophotometer (Perkin Elmer) with a 2.5 nm or 5.0 nm band-pass. The excitation 
fluorescence intensity ratio was calculated by measuring the emission intensity at 535 
nm with excitation wavelengths at 490 nm and 440nm respectively. 
Calibration of the intracellular pH (pH；) 
Intracellular pH was calculated using the nigericin-high K+ approach (Thomas et 
al., 1979) with minor modification. The internal and external pH of the loaded cells was 
equilibrated with isosmotic buffer containing 130 mM KCl and 1 mM MgCl� with 2 \xM 
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nigericin. A 5-min incubation was sufficient. Buffers ranged from pH 6.4 to 8.0 were 
used. 
DNA extraction from mammalian cells 
The cells (-1x10^) in a 6-well plate were washed with PBS once. After then, the 
cells were dissolved in 400 i^l lysis buffer (100 mM EDTA, 1% SDS and 200 mM Tris-
HCl, pH 8.3) in a 1.5 ml eppendorf tube. The tube was shaken until no cell debris left. 
20 lull of 10 mg/ml proteinase K was added to each tube and incubated at 37 for at 
least 2 hr. The samples were cooled to room temperature and mixed with 150 fil 
saturated NaCl solution. The tubes were shaken vigorously and centrifuged at 3,900 x g 
for 15 min. The supernatant was transferred to a new tube and mixed with 1 ml cold 
absolute ethanol. The mixture was then centrifuged at 13,600 x g at 4 for 20 min. 
The DNA pellet was washed with 70% ethanol once and allowed to dry in an oven. 
Finally, 20 |LI1 TE buffer containing 0.2 mg/ml RNase A was added and incubated 
at 37 for 90 min. The samples were then electrophoresed in a 1 % agarose gel and 
stained with ethidium bromide. 
Phenol-chloroform extraction 
Equal volume of phenol: chloroform : isoamyl alcohol (24:24:1, v/v) was added to 
the sample. The sample was then shaken vigorously and centrifuged at 13,600 x g for 
15-30 min. The upper, aqueous phase was transferred to a new tube. Equal volume of 
chloroform was added. The centrifugation stated previously was repeated, two volumes 
of ice-cold absolute ethanol was added to the upper phase and mixed vigorously. The 
sample was stood on ice for 1 hr and centrifuged at 13,600 x g for 45 min. The 
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supernatant was discarded and the pellet was washed with 70 % ethanol once. The DNA 
pellet was allowed to dry at room temperature. The DNA was reconstituted in 5 
dHsO and run in a 20 % polyacrylamide gel. The gel was then stained with SYBR 
Green I nucleic acid gel stain. 
Phosphofructokinase-1 (PFK-1) activity determination 
6x1 O^  cells per well were seeded on a 6-well plate. After treatment, the cells were 
trypsinized and washed with PBS twice. The cells were resuspended in ice-cold 0.2M 
KCl containing 0.005M Tris-HCl buffer (pH 7.4) and O.OOIM dithiothreitol. Cells were 
then ruptured by sonicator cell disruptor (Ultrasonic, Inc.) on ice. The supematants were 
obtained by centrifugation at 20,000g for 50 min at 4 The enzymatic activity was 
determined as described by Kemp (Kemp, 1975) with minor modification. In brief, the 
enzymatic reaction of PFK was coupled to three ‘Following Enzymes，,aldolase, triose 
phosphate isomerase and glycerol phosphate dehydrogenase, which were present in 
excess. Thus, PFK activity was the rate limiting step for the reactions. Those reactions 
were : 
Fructose-1,6-bisphosphate ^ Glyceraldehyde-3-P +dihydroxyacetone-P 
Glyceraldehyde-3-P ^ Dihydroxyacetone-P 
Dihydroxyacetone-P + NADH + H+ ^ Glycerol-3-P + NAD+ 
These coupling reactions led to a decrease in NADH, resulting in the fall of 
absorbance at 340 nm while the change was proportional to the activity of PFK. The 
PFK activity was calculated by the following equation : 
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PFK activity — AA/min x Total volume x 1000 
(U/Lfxg ) 6.22 X Sample volume x LP x Amount of proteins 
lU = amount of enzymes which produce 1 jumole of NAD per min under the condition 
of the assay. 
10 of the supernatant was used to carry out BCA method in order to estimate the 
protein amounts. 
(LP - Light path = 1 cm ; 6.22 is the molar extinction coefficient of NAD) 
Statistical Analysis 
Data were expressed as the mean values 土 S.D. in different experiments. The 
relative percentage was calculated by dividing the absorbance of treated cells by that of 
untreated cells multiplied by 100. Student's t test was performed in the experiment 
indicated and p<0.05 was considered as significant. 
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3. Results 
3.1 The characteristics of MCF-7 and MDA-MB-231 cells 
The specimens of carcinoma of the breast are usually composed of both estrogen 
receptor-positive and negative cells. Determination of the estrogen receptor (ER) status 
is a common practice in prognosis of breast cancer. Receptor-negative breast carcinoma 
does not mean there are no estrogen receptors in tumor cells at all. In fact, the receptor 
levels less than 3-5 femtomoles per milligram of cytosol proteins would be considered 
as receptor-negative. In addition, breast carcinoma was proposed to have the ability to 
progress from estrogen receptor-positive to receptor-negative and was observed in in 
vivo experiment (Clarke et al” 1989). On the other hand, ER-negative breast cancer 
cells were usually more invasive and about 30% of metastases from primary breast 
cancer were found to have loss of ER (Kuukasjarvi et al,, 1996). Therefore, two 
different breast cancer cell lines were used in this study so as to mimic the different 
stages of breast carcinoma. 
MCF-7 cell line, one of the estrogen-receptor positive human breast cancer cell 
line and MDA-MB-231 cell line, an estrogen-receptor negative cell line were used. 
MDA-MB-231 cell was found to be more malignant and invasive than MCF-7 cell 
(Carmeci et al,, 1998). It was proposed that estrogen could modulate the invasive 
capacity of estrogen-receptor positive cells (Long & Rose, 1996). It was known that the 
most frequent cause of death in breast cancer patients was due to the metastasis of 
tumor cells rather than the local effects of the tumor. Therefore, characterization of 




Antisense Inhibition of Glucose Transporter 5 on Breast Tumor Cells 
From figure 3.1, the growth curves of both cell lines were shown. The doubling 
time of MDA-MB-231 cells was found to be 33 hr while that of MCF-7 cells was about 
41 hr. It seemed that MDA-MB-231 cells had a higher proliferation rate than MCF-7 
cells. 
Estrogen receptor determination was usually performed in order to evaluate the 
tumor responses to endocrine therapy. There was a close relationship between the 
success of an endocrine therapy and the estrogen receptor status in breast cancer 
patients. It was found that approximate 60% of ER positive patients responded to 
endocrine therapy (Kuukasjarvi et al., 1996). Tamoxifen was one of the most common 
agents used in endocrine therapy. Normally, estrogen will bind to the cytosolic estrogen 
receptor. This ligand-receptor complex will then be translocated into the nucleus and 
bind to the corresponding estrogen response elements. In consequence, transcription of 
a particular gene is activated and enhances the growth of tumor cells. Tamoxifen, on the 
other hand, acts as an antiestrogen to compete with estrogen for the receptors and block 
the effect of estrogen on breast tumor cells. However, a proportion of patients failed to 
respond to tamoxifen as well as other antiestrogen. One of the suggested reasons was 
due to the loss of ER in those patients. This failure of antiestrogen was also 
demonstrated by testing the effect of tamoxifen on both cell lines. The anti-proliferative 
effect on ER positive MCF-7 cells was more pronounced than that of ER negative 
MDA-MB-231 cells (Fig 3.2). This ineffectiveness pinpointed the main disadvantage in 
using tamoxifen on treating breast cancer. Antisense therapy, on the other hand, can 
supplement this weakness because its action mechanism does not depend on the 
estrogen receptor status. 
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Fig 3.1 The growth curves of MDA-MB-231 and MCF-7 breast tumor cells. 
For MDA-MB-231 cells, 1x10^ cells per well were seeded in 6-well plate and incubated 
in humidified atmosphere at 37 and 5 % CO2 The day after overnight was noted as 
day 0. On each day, the cell number was counted by trypan blue exclusion assay as 
described in Materials and Methods. Each point represented the mean value of triplicate 
土S.D. (A) 
For MCF-7 cells, the curve was adapted from my colleague Mr. Tsui. 2x10^ cells per 
well was seeded in a 96-well plate and incubated in the same conditions as MDA-MB-
231. One day after incubation was also noted as day 0. The cell confluence was 
measured by MTT assay. Cell confluence after 72 hr was set as 100%. Each point 
represented the mean value of 5 replicates 士S.D. (B) 
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Fig 3.2 The dose-response curve of MCF-7 and MDA-MB-231 cells towards 
tamoxifen. 
Both cell lines were seeded at 2x10; cells per well in a 96-well plates and incubated 
overnight in humidified atmosphere at 3 7 � C and 5 % CO� . 10 mM stock tamoxifen (in 
100 % ethanol) was diluted into appropriate concentrations in RPMI 1640 medium 
supplemented with 10 % FCS and 5% antibiotics. Each well was added with 200 
tamoxifen in medium and incubated for further 48 hr at 37 After then, medium of 
each well was discarded and MTT assay was carried out as described in Materials and 
Methods. The percentage of inhibition was calculated by subtracting 100 % by the 
percentage of viability. Each concentration represented the mean value of 5 replicates 
土S.D. 
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3.2 Trend of uptake of antisense oligonucleotides in MCF-7 and MDA-
MB-231 cells 
To exert their effects on the target sites, antisense oligonucleotides must enter the 
cytoplasmic or nucleic compartments of cells. Therefore, a successful delivery of 
antisense oligonucleotides is one of the main considerations in achieving the therapeutic 
goal in cancers. However, since oligonucleotides are negatively charged, their cell 
membrane permeability is low and this will be a major problem for clinical application. 
A successful delivery of oligonucleotides usually means there is an efficient uptake into 
the cellular compartments and the concomitant release of the oligonucleotides from the 
endosomes. The uptake mechanism of oligonucleotide has been extensively studied. By 
using FITC labeled oligonucleotides, the oligonucleotide transport into living cells was 
characterized. It was generally accepted that endocytosis was involved in the uptake of 
oligonucleotides (Nakai et al., 1996). It was found that the internalization of the 
oligonucleotides was inhibited by sodium azide which was able to block the 
internalization of endocytotic vesicles. Besides, addition of chloroquine, a 
lysosomatropic agent, markedly increased the intracellular fluorescence (Loke et al” 
1989). Both evidences suggested the involvement of endocytosis. Moreover, a 61-63 
kDa and a 80 kDa membrane proteins were identified to be responsible for mediating 
the transport in two different cell lines (Laktionov et al., 1996). In polymorphonuclear 
leukocytes, a heparin-binding integrin, Mac-1, was also found to be the cell surface 
receptor for oligodeoxynucleotides that can mediate their internalization (Benimetskaya 
et al-, 1997). This type of transport mechanism was time-, sequence- and sometimes cell 
type-dependent. 
The characterization of the uptake in MCF-7 and MDA-MB-231 cells was also 
investigated. FITC-labeled 15 and 21 base oligonucleotides were incubated with the 
^ ^ ^ ^ 41 
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cells in serum-free medium. Those intracellular oligonucleotides were chased by using 
flow cytometry. From the results, the uptake of oligonucleotides was rapid at the first 3 
hours and increased gradually as the time passed by (Fig 3.3). This demonstrated that 
the uptake process was time-dependent. 
Nevertheless, this endocytotic transport efficacy of the pure oligonucleotides was 
so poor that their biological efficacy was hindered. There are then numerous methods 
introduced to enhance the cellular uptake of oligonucleotides. For example, 
microinjection, electroporation and oligonucleotide linked to peptides were proven to 
increase the accumulation of oligonucleotides in intracellular compartments. One of the 
most common practices was the usage of liposomes. They allow the encapsulation of 
either aqueous molecules in the aqueous cavity or of lipophilic drugs into the membrane. 
Since the usefulness of liposomes, a number of modifications were introduced to 
enhance the role of being a carrier of a wide variety of drugs. One of them, which was 
used in this project, was cationic liposome known as lipofectin. This liposome is a 
mixture of univalent cationic lipid DOTMA (N-[l-{2,3，-dioleyloxy}propyl]-N,N,N-
trimethylammonium chloride) and neutral helper lipid DOPE (dioleoyl 
phosphatidylethanelamine) in a 1:1 (w/w) ratio. The oligonucleotide can interact 
spontaneously with DOTMA to form lipid-DNA complexes. This complex formation is 
due to ionic interactions between the positively charged groups on the DOTMA 
molecules and the negatively charged phosphate groups on the DNA (Bijsterbosch et al., 
1997). The primary route of liposome entering the cells was found to be endocytic 
pathway via clathrin-coated pits (Maurer et al., 1999). When sufficient lipofectin was 
used, the negative charge of the oligonucleotide would be completely neutralized and 
provided a complex with a net positive charge that could associate with the negatively 
charged surface of the cell. Thus, the uptake of oligonucleotide was greatly enhanced in 
different cell lines (de Lima et al., 1999). The internalization of oligonucleotides was 
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Fig 3.3 The trend of uptake of FITC-antisense oligonucleotide (15 bases) in MDA-
MB-231 and MCF-7 cells. 
2x10^ cells per well were seeded in a 6-well plate overnight. 2 |LIM F I T C labeled 
antisense oligonucleotides in serum-free medium were added to each well and incubated 
at 3 7 � C with 5 % CO2. At the indicated time, the cells were washed with PBS and 
trypsinized. The intensity of green fluorescence was analyzed by flow cytometry. There 
was a gradual shift of the peak within 15 hr incubation. 
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also enhanced in MCF-7 and MDA-MB-231 cells. From figure 3.4, lipofectin enhanced 
the uptake of oligonucleotide at 2 \iM up to 2 folds at 15 hr transfection in MCF-7 cells 
while 53 folds more uptake was increased in MDA-MB-231 cells. The enhancement in 
MDA-MB-231 cells was more pronounced. 
Moreover, the saturable characteristic was observed in both cell lines after 15 hr 
transfection. The uptakes at 15 hr and 20 hr were more or less the same. No further 
increment was observed at this concentration. If 15 base-unlabeled oligonucleotide was 
co-incubated with the lipofectin carried FITC-oligonucleotide, the amount of FITC-
oligonucleotide entering the cells was reduced at the same period of time. This indicated 
that pure oligonucleotide may compete the same route of transport with the lipofectin-
DNA complex when entering the cells. These routes include passive diffusion or 
pinocytosis which were considered as the minor transport mechanisms. Furthermore, 
the uptake pattern of 21-base antisense oligonucleotides was different between the two 
cell lines (Fig 3.5). The transport of the 21-base oligonucleotides was less efficient in 
MDA-MB-231 cells but was more efficient in MCF-7 cells when compared with that of 
15-base oligonucleotides in aid of lipofectin. That meant the length and the sequence as 
well as the cell type could affect the pattern of oligonucleotide transport. Besides 
enhancement of uptake, encapsulation of the oligonucleotide also protected it from 
degradation by nucleases (Capaccioli et al., 1993). However, lipofectin itself was toxic 
if it was used at high amount and prolonged time of incubation with cells (Fig 3.6), 
although the toxicity would be lower after complex formation. Since the transport of 
oligonucleotide was saturated after 15 hr, the transfection time was set to be 15 hr for 
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Fig 3.4 The enhancement of lipofectin on the uptake of 15-base antisense 
oligonucleotides. 
2x10^ cells per well were seeded in a 6-well plate overnight. 2 (iM FITC labeled 
oligonucleotides were mixed with lipofectin in 1:1 ratio (w/w) in serum-free medium 
and added to cells. The uptake of oligonucleotides after 15 hr was compared with the 
uptake of oligonucleotides with the aid of lipofectin after 15 hr (LlShr) and 20 hr (L20 
hr) respectively. Unlabeled oligonucleotides (blue line) were alscnadded to the serum-
i ‘ free medium after the mixing of lipofectin and oligonucleotides. The lipofectin-DNA 
mixture was then added to cells for 15 hr incubation. 
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Fig 3.5 Comparison of the uptake of 15 and 21-base antisense oligonucleotides. 
2x10^ cells per well were seeded in a 6-well plate overnight. 2 (iM FITC labeled 
oligonucleotides were mixed with lipofectin in 1:1 ratio (w/w) in serum-free medium 
and the mixture was added to cells. The uptake of oligonucleotides after 15 hr was 
compared between 15-base antisense oligonucleotides and 21-base oligomers by using 
the flow cytometry. 
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Fig 3.6 The relation between the toxicity of lipofectin and incubation time towards 
MDA-MB-231 cells. 
2x104 cells/well were seeded on a 96-well plate. Different concentrations of lipofectin 
in 100 serum-free medium were added to the cells from 9 to 24 hr. Each well was 
washed with PBS and replaced with fresh complete medium for further 24 hr incubation. 
The cell density was measured by MTT assay. Serum-free medium treated cells were 
used as the relative controls. 
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3.3 The integrity of the oligonucleotide in serum-free medium during 
transfection 
The normal phosphodiester bond was easily cleaved by nucleases in serum or 
culture medium. The major nuclease activity in serum and medium was 3，exonuclease 
activity. For successful application as therapeutic agents, the stability of 
oligonucleotides should be maintained throughout the transfection period. In addition, 
the oligomers should have a long half-life in order to perform their effects as long as 
possible. In this study, phosphorothioate oligonucleotides were used so as to prolong 
their stability. The integrity of antisense oligonucleotides in serum-free medium was 
analyzed by gel electrophoresis. After incubated in serum-free medium, the 15-base 
antisense oligonucleotides were extracted by phenol-chloroform method and the 
electrophoresis of the samples were performed in a 20% polyacrylamide gel with 5 M 
urea. From figure 3.7, the major band was the 15-base oligonucleotide as the negative 
control band after incubated in serum-free medium from 3 to 8 hr. Trace amount of 
degradation products could be found at lower position after 15 hr of incubation. 
Moreover, the application of lipofectin as a carrier did not have any significant change 
in the degradation pattern. This may be due to the fact that most of the oligonucleotides 
have remained intact and any subtle change was difficult to detect. Combined with the 
results obtained in the upper part, it was suitable to use 15 hr transfection period in the 
following experiments to achieve both optimization of uptake and maintenance of the 
integrity during the process. 
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Fig 3.7 The integrity of the 15-base antisense oligonucleotide in serum-free medium 
at different incubation times. 
The antisense oligonucleotide was incubated with serum-free medium for different 
times. The oligonucleotide was extracted by phenol-chloroform extraction and the 
samples were run in 20% polyacrylamide gel with 5 M urea. No degradation could be 
detected at 3, 5 and 8 hr. Trace amount of degraded products could be detected in 15 and 
20 hr as compared with the positive control (+ve). The lipofectin complexed 
oligonucleotide (LI5) showed similar pattern as the native oligonucleotide after 
incubated for 15 hr in serum-free medium. 
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3.4 Detection of effects of Gluts antisense oligonucleotides on breast 
tumor cells -MTT assay 
The phosphorothioate Glut5 antisense oligonucleotides were then applied to cell 
culture study. The effects of the antisense oligonucleotides were investigated by using 
MTT assay. Both 15-base and 21-base oligonucleotides were mixed with lipofectin in 
ratio 1:1 (w/w) in serum-free medium. The lipofectin-DNA complex was incubated 
with each of the cell line at 37 for 15 hr. After then, the serum-free medium was 
replaced by fresh medium and the cells were incubated for further 48 hr. The 
antiproliferative effect was studied by MTT assay. Sense-sequence oligonucleotides 
were used as a control for the indication of any non-specific effects caused by the 
transfection. 
For the 15-base Glut5 antisense oligonucleotide, antiproliferative effect was 
observed in both MDA-MB-231 and MCF-7 cells (Fig 3.8 & 3.9). The effect was 
concentration dependent. An increase in the concentration of the antisense 
oligonucleotide resulted in an increase in the antiproliferative effect. The non-antisense 
effect was relatively low as indicated by a higher percentage of survival in sense 
oligonucleotide treatment. However, as shown in MCF-7 cells, the non-specific effect 
increased as the concentration of sense oligonucleotide increased. This non-specific 
effect was mainly due to the binding of the phosphorothioate oligonucleotide to a wide 
variety of proteins in sequence-independent manner that would be toxic to cells 
(Wagner, 1994). On the other hand, the antiproliferative effect of the antisense 
oligonucleotide was similar in both cell lines. Similar percentage was observed at the 
same concentration of antisense oligonucleotide. 
For the 21-base antisense oligonucleotide, similar trend as the 15-base anti-Glut5 
oligonucleotide was observed (Fig 3.10). The effect of the antisense oligonucleotide 
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Fig 3.8 The effect of GlutS antisense oligonucleotide on the growth of MCF-7 cells. 
Different concentrations of oligonucleotide as indicated was added to 2x10^ cells/well 
in 96-well plate. Equal amount of lipofectin (w/w) was used to complex with the 
oligonucleotide in serum-free medium. After 15 hr transfection, the cells were 
recovered in fresh complete medium for further 48 hr. The percentage of cell confluence 
relative to serum-free treated control was measured by MTT assay. Sense sequence (S) 
was also added to differentiate any non-specific effect observed in antisense treatment 
(AS). Each bar represented the mean value of 5 replicates 土S.D. 
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Fig 3.9 The effect of GlutS antisense oligonucleotide on the growth of MDA-MB-
231 cells. 
Different concentrations of 15-base oligonucleotide as indicated was added to 2x1 O* 
cells/well in 96-well plate. Equal amount of lipofectin (w/w) was used to complex with 
the oligonucleotide in serum-free medium. After 15 hr transfection, the cells were 
recovered in fresh complete medium for further 48 hr. The percentage of cell confluence 
relative to serum-free treated control was measured by MTT assay. Sense sequence (S) 
was also added to differentiate any non-specific effect observed in antisense treatment 
(AS). Each bar represented the mean value of 5 replicates 士S.D. 
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Fig 3.10 The effect of 21-base GlutS antisense oligonucleotide on the growth of 
MCF-7 and MDA-MB-231 cells. 
Different concentrations of oligonucleotide as indicated was added to 2x1 O^  cells/well 
in 96-well plate. Equal amount of lipofectin (wt/wt) was used to complex with the 
oligonucleotide in serum-free medium. After 15 hr transfection, the cells were 
recovered in fresh complete medium for further 48 hr. The percentage of cell confluence 
relative to serum-free treated control was measured by MTT assay. Sense sequence (S) 
was also added to differentiate any non-specific effect observed in antisense treatment 
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was also concentration dependent. Moreover, it seemed that the antiproliferative effect 
on MCF-7 cells was less effective than that on MDA-MB-231 cells. The non-specific 
effect of the MDA-MB-231 cells was also lower when compared with that of the MCF-
7 cells. 
To verify the specificity of anti-Glut5 oligonucleotide on cells that expressed GlutS, 
the antisense oligonucleotide was applied to cell line without Glut5 expression. HepG2 
cells were chosen. HepG2 cell line was a hepatoblastoma cell line obtained from a 15 
year-old Caucasian male in Argentina (Aden et al., 1979). It was found that liver cancer 
cells expressed Glutl, Glut2 and Glut3 but no Glut5 expression was detected 
(Yamamoto et al., 1990). Therefore, HepG2 cell line was a good indicator for the 
specificity of the Glut5 antisense oligonucleotide's effect. HepG2 cells were cultured in 
RPMI 1640 at the same conditions as the two breast cancer cell lines. The effect of 15-
base antisense oligonucleotide was investigated. The cells were all treated with the 
lipofectin-DNA complex by the same procedures as described before. From the figure 
3.11, the antiproliferative effect of the antisense oligonucleotide on HepG2 cells was 
much less than the effect on MDA-MB-231 cells. The difference was found to be 
significant and level of antisense effect on HepG2 cells was similar with the non-
specific effect caused by the sense-sequence oligonucleotide. This result indicated that 
Gluts antisense oligonucleotide was more effective on cells with Glut5 expression. For 
those cells without Glut5 expression, they were likely to be affected only by the non-
sequence specific effects. 
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Fig 3.11 Comparison of the effect of GlutS antisense oligonucleotide on HepG2 cells 
and MDA-MB-231 cells. 
Different concentrations of 15-base Glut5 antisense oligonucleotides complexed with 
lipofectin at ratio 1:1 (w/w) were transfected for 15 hr. The antiproliferative effect on 
HepG2 cells was compared with the serum-free medium treated HepG2 cells. The 
antiproliferative effect on HepG 2 cells at 5 [iM was significantly lower than that on 
MDA-MB-231 cells. The effect on HepG2 cells was mainly due to non-sequence 
specific effect as indicated by the sense-sequence treated cells. Each bar was the mean 
value of five replicates 士S.D. The significance of the differences were analyzed by 
student's t-test (*p<0.001). 
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3.5 Detection of the antiproliferative effect by trypan blue exclusion 
assay and thymidine incorporation 
MTT is a tetrazolium salt that can be taken up into cells and reduced in a 
mitochondria dependent reaction to yield a formazan product which is impermeable to 
cell membrane. The reduction of MTT provides an indication of mitochondrial integrity 
and activity which, in turn, can be interpreted as a measure of viability of cells. 
Nevertheless, it is a sensitive measure of the cytotoxicity but not a well indicator of the 
proliferation of cells. Additional methods were used in order to verify the 
antiproliferation exerted by the antisense oligonucleotides. Trypan blue exclusion assay 
is a direct measure of viable cell number by making use of the dye trypan blue. Viable 
cells are impermeable to the dye while the dead cells will take up the dye and are 
stained by it because of the breakdown of membrane integrity. 
Direct cell number was measured after transfection of the Glut5 antisense 
oligonucleotide at different time points. 5 |LIM 15-base antisense oligonucleotide was 
carried by the same amount of lipofectin to transfect with both cell lines. At a particular 
time point, the cells were trypsinized and trypan blue exclusion assay was carried out. 
From figure 3.12, both cell lines were counted after 15 hr transfection. At that time, the 
number of cells treated with serum-free medium and Glut5 antisense were more or less 
the same. On one or two post-transfection days, the differences between the serum-free 
control and antisense treated cells increased. These results indicated that the growth rate 
of the antisense treated cells was lower than that of the serum-free treated cells. 
For eukaryotic cells, they grow through different phases that are known as cell 
cycle. In dividing cells, replication of the DNA of each chromosome is necessary before 
the beginning of mitosis. During this period, also known as S phase, the initiation and 
completion of synthesis can be detected by monitoring the incorporation of radioactive 
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Fig 3.12 Direct cell number counting by trypan blue exclusion assay. 
After treated with serum-free medium (SF) and Glut5 antisense oligonucleotide (AS), 
the tumor cells were trypsinized and counted in a hemacytometer. Cells were counted 
after 15 hr of transfection (15) and different time points recovered from transfection as 
indicated. Data were expressed as the mean value of triplicate 土S.D. 
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DNA precursors [methyl-^H]-thymidine. The higher incorporation of the labeled 
thymidine means the more active they grow. Firstly, 2 juM 15-base antisense oligomer 
was added to cells as described in Materials and Methods. After recovery from 
transfection at different time points, tritium labeled thymidine was added to cells for 
further 3 hr. The amount of uptake was measured by liquid scintillation counting. From 
figure 3.13, the counts per protein amounts in antisense treated tumor cells were lower 
than both serum-free and sense oligonucleotide controls. The differences in both cell 
lines one day after transfection were significant when compared with sense 
oligonucleotide treatment. Antiproliferative effect could also be observed until the 
second day after transfection (Fig 3.14). Data were expressed as the mean value of 
triplicate ±S.D. The differences between sense and antisense oligonucleotides treated 
tumor cells were significant (p<0.001). 
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Fig 3.13 The antiproliferative effect of GlutS antisense oligonucleotide on breast 
tumor cells after one day of transfection. 
After one-day recovery from transfection, [methyl-^H] thymidine in 0.5 [iCi was added 
to cells for further 3 hours. The cells were then washed with PBS and the precipitated 
by 10% TCA. The cells were lysed by 0.1% SDS and IM NaOH and the amount of 
thymidine uptake was measured by scintillation counting. 5 |al of the cell lysate was 
used for measurement of the protein amounts. Data were expressed as the mean value of 
triplicate 土S.D. The significance of the differences were analyzed by student's t-test (* 
p<0.02, **p<0.001). 
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Fig 3.14 The antiproliferative effect of GlutS antisense oligonucleotide on breast 
tumor cells after two days of transfection. 
After two days recovery from transfection, [methyl-^H] thymidine in 0.5 j^Ci was added 
to cells for further 3 hours. The cells were then washed with PBS and the precipitated 
by 10% TCA. The cells were lysed by 0.1% SDS and IM NaOH and the amount of 
thymidine uptake was measured by scintillation counting. 5 |ul of the cell lysate was 
used for measuring of the protein amounts. Data were expressed as the mean value of 
triplicate 土S.D. The significance of the differences were analyzed by student's t-test (* 
pO.OOl). 
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3.6 Cell cycle analysis and DNA extraction 
As the anti-Glut5 oligonucleotide exerted antiproliferative effect on both breast 
cancer cell lines, it was speculated whether there was any change in the pattern of cell 
cycle after treating with Glut5 oligomers. It is known that many agents carry out 
antiproliferative effect by interference of the cell cycle distribution. For example, 
tamoxifen can exert antiproliferative effect on breast cancer cells by blocking cells in 
G1 phase (Lykkesfeldt et al； 1984). As before, 2 juM 15-base antisense oligonucleotide 
mixed with lipofectin was transfected with cells. The cells were recovered by 
replacement of fresh medium after 15 hr transfection. At an appropriate time, the cells 
were trypsinized and stained with propidium iodide. The cell cycle distribution was 
analyzed by flow cytometry. 
In figure 3.15, the cell cycle pattern of MCF-7 was shown. There was no 
observable accumulation of cell population in G1 phase after the treatment of anitsense 
oligonucleotide for one day. Nevertheless, there was a slight arrest in G1 phase in 
antisense treated cells on the second day of recovery. The results obtained from MDA-
MB-231 cells were similar (Fig 3.16). There was no significant arrest of cell proportion 
in G1 phase at all. The antiproliferative effect of GlutS antisense oligonucleotide did not 
cause measurable interference on cell cycle as detected by this method. It was 
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Fig 3.15 Cell cycle analysis of MCF-7 cells on one and two days after transfection. 
The cells were stained by PI and analyzed by flow cytometry. The proportion of cells in 
different phases were measured by the 'Cell Fit, program (A-one day; B-two days). 
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Fig 3.16 Cell cycle analysis of MDA-MB-231 cells on one and two days after 
transfection. 
The cells were stained by PI and analyzed by flow cytometry. The proportion of cells in 
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Apoptosis is a common mechanism leading to cell death. One of the characteristics 
of apoptosis is the phenomenon of DNA fragmentation. To test whether antisense 
oligonucleotide induced apoptosis, 2 |LIM 15-base antisense oligonucleotide mixed with 
lipofectin was transfected with cells and the nuclear DNA was extracted. The nuclear 
DNA was then electrophoresed in a 1% agarose gel. The results showed that Glut5 
antisense suppressed cell growth in the absence of apoptosis induction (Fig 3.17). There 
was no detectable DNA fragmentation in antisense treated cells as well as the two 
controls. The total nuclear DNA in both tumor cells remained intact after different 
treatments. 
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Fig 3.17 Nuclear DNA isolated f rom MCF-7 and MDA-MB-231 cells. 
DNA fragmentation, the characteristic of apoptosis, was not detected in both cell lines 
after transfection with anti-Glut5 oligonucleotides. The nuclear DNA was extracted 
from cells one and two days after transfection. Lane 1，serum-free control; lane 2, sense 
control; lane 3, antisense treated cells; lane 4, serum-free control; lane 5, sense control; 
lane 6, antisense treated cells; M, marker. 
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3.7 Suppression of GlutS mRNA detected by RT-PCR 
In theory, the antisense oligonucleotides will bind to the corresponding region on 
the Glut5 mRNA after entering into the cytosol. Since phosphorothioate DNA-RNA 
duplex is the substrate for RNase H, the enzyme will break down the mRNA. In 
consequence, the level of Glut5 mRNA will be reduced. Therefore, measurement of the 
change of GlutS mRNA level in antisense treated cells will reflect the effectiveness of 
the operating antisense mechanism. 
After treating with 4 |LIM of oligonucleotide carried by lipofectin, the total RNA 
were extracted from both cell lines and were used to synthesize the first strand cDNA 
by the action of reverse transcription. The products were then amplified by specific 
primers of the GlutS mRNA. The normalization of the bands was done by amplification 
of another gene called GAPDH which was a house-keeping gene. From figure 3.18， 
three different cycles of amplification of the GAPDH were tested. There was an 
increase in the intensity of the bands from 20 to 30 cycles. 25 cycles of amplification 
was chosen in this gene so as to make sure that the bands were normalized and there 
was no saturation of the PGR products. 
As observed in figure 3.19，the level of GlutS mRNA in MCF-7 cells was 
suppressed after 5 hr of the transfection when compared with the level in both serum-
free and sense sequence treated cells. At 48 hr post-transfection, the effect of the Glut5 
antisense oligonucleotide was still valid. For MDA-MB-231 cells, suppression of Glut5 
mRNA was observed at 5 hr and 24 hr after the transfection (Fig 3.20). When 
comparing the level of GlutS mRNA in antisense treated tumor cells alone, the degree 
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Fig 3.18 The linear relationship between the number of cycles and the amount of 
product amplified in GAPDH. 
Total RNA from MDA-MB-231 cells were extracted and used to synthesize the first 
strand cDNA. The cDNA product was then amplified by specific primers for GAPDH. 
A product about 500 base pairs was obtained. 
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Fig 3.19 The suppression of Glut5 mRNA in MCF-7 cells after treatment of 
antisense oligonucleotide. 
Total RNA was extracted from cells treated with serum-free medium (SF), sense 
sequence (S) and antisense oligonucleotide (AS) respectively. The RNA was then 
reverse transcripted into cDNA which would carried out PGR by specific primers. The 
amounts of samples added were normalized by amplification of the glyceraldehyde-3 -
phosphate dehydrogenase (GAPDH). Primers flanking a 700 base pairs product 
amplified the GlutS mRNA. The PGR products were then run in 1 % agarose gel and 
stained with ethidium bromide. 
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Fig 3.20 The suppression of GlutS mRNA in MDA-MB-231 cells after treatment of 
antisense oligonucleotide. 
Total amounts of RNA were extracted from cells treated with serum-free medium (SF), 
sense sequence (S) and antisense oligonucleotide (AS) respectively. The RNA was then 
reverse transcripted into cDNA which would carried out PGR by specific primers. The 
amounts of samples added were normalized by amplification of the glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). Primers flanking a 700 base pairs product 
amplified the GlutS mRNA. The PGR products were then run in 1 % agarose gel and 
stained with ethidium bromide. 
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Fig 3.21 Comparison of the GlutS mRNA in antisense oligonucleotide treated 
MCF-7 and MDA-MB-231 cells at dilTerent time points. 
Total RNA was extracted from cells after recovery at the time point indicated. The RNA 
was then used to synthesize cDNA and amplified with specific primers. The amounts of 
samples amplified were normalized by amplification of the housekeeping gene， 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Specific primers flanking a 700 
base pairs product amplified the GlutS mRNA. The PCR products were then run in 1 % 
agarose gel and stained with ethidium bromide. 
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It was then speculated that the amount of Glut5 mRNA in antisense treated cells 
would be recovered after 48 hr of transfection. From figure 3.22, the levels of GlutS 
mRNA were investigated at 72 hr after transfection. In both antisense treated cell lines, 
the amount of GlutS mRNA were recovered back to the same level as those in serum-
free and sense sequence treated cells. Single dose of anti-Glut5 oligonucleotide could 
exert its effect and it lasted for about two days. 
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MCF-7 cells MDA-MB-231 cells 
Fig 3.22 Comparison of the Gluts mRNA in MCF-7 and MDA-MB-231 cells after 
72 hr of transfection. 
The level of Glut5 mRNA in serum-free medium (SF), sense oligonucleotide (S) and 
antisense oligonucleotide (AS) treated cells were compared after recovery from 
transfection for 72 hr. 
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3.8 Suppression of translation of Gluts proteins as indicated by 
Western blotting 
The ultimate goal of the antisense oligonucleotides is to suppress the gene 
expression at protein level. By measuring the change of protein amount of the target 
gene, the effect exerted on the tumor cells can be verified whether it is carried out 
through antisense-specific action mechanism or just under non-specific action. 
Therefore, the investigation of the change in GlutS protein expression is inevitable. 
Sense-sequence treated cells were used as the relative controls to antisense treated cells. 
All the samples were normalized by measurement of the protein amounts using the 
BCA method. Each sample at 25 |ag was added and separated through a 8% SDS PAGE. 
The Gluts proteins were recognized by anti-rabbit Glut5 antibodies and the signal was 
developed through ECL. The intensities of bands were compared by using densitometer. 
From the results, after recovery from transfection for one day, the amount of Glut5 
proteins in antisense treated cancer cells were lower than that of the sense-sequence 
treated cells (Fig 3.23). Combined with the results in RT-PCR, the reduction of GlutS 
mRNA after one day of transfection had resulted in a decrease of protein level encoded 
by the Glut5 mRNA. This suppression was attainable in both MCF-7 and MDA-MB-
231 cells. In MCF-7 cells, the Glut5 protein amounts were about 4 % less than the 
sense-sequence treated cells while the Glut5 protein amounts were about 20 % less in 
MDA-MB-231 cells. From figure 3.24, the decrease in protein level could also be 
observed on the second day after transfection. In MCF-7 cells, the expression of Glut5 
protein was more enhanced and it was about 35 % less than that of the sense-sequence 
treated cells was obtained. On the other hand, the GlutS protein level was about 20 % 
less than the sense treated MDA-MB-231 cells. It seemed that the inhibition of protein 
synthesis would last during the suppression of mRNA as indicated by Western blotting. 
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Fig 3.23 The suppression of GlutS proteins in antisense treated MCF-7 and MDA-
MB-231 cells after one day of transfection. 
Cells with different treatments were trypsinized and the proteins were extracted as 
described in Materials and Methods. The proteins samples were then run in 8% SDS 
PAGE and followed by Western blotting. The GlutS proteins were blotted against anti-
rabbit Gluts antibodies and developed by ECL method. The intensities of the bands 
were analyzed by densitometer and the band of sense oligonucleotide treatment was 
calculated as a hundred percent. (A: MCF-7; B: MDA-MB-231) 
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Fig 3.24 The suppression of GlutS in protein levels two days after transfection. 
After two days of transfection, cells with different treatments were trypsinized and the 
proteins were extracted as described in Materials and Methods. The protein samples 
were then run in 8% SDS PAGE and followed by Western blotting. The GlutS proteins 
were blotted against anti-rabbit GlutS antibodies and developed by ECL method. The 
intensities of the bands were analyzed by densitometer and the band of serum-free 
treatment was calculated as a hundred percent. (A: MCF-7 cells; B: MDA-MB-
231 cells) 
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3.9 Measurement of the fructose and glucose uptake in MCF-7 and 
MDA-MB-231 cells after antisense treatment 
Glut5 was found to be a facilitative transporter with low Km for fructose but only 
mediated glucose transport with a very low capacity (Rand et al” 1993; Darakhshan et 
al,, 1998). As the Glut5 expression was suppressed, it was conceivable that Glut5 
mediated transport would also be inhibited. Thus, decrease in the level of Glut5 proteins 
would also lead to reduction in the uptake of fructose after treated with antisense 
oilgonucleotides. We proposed that the blockade of fructose uptake in breast tumor cells 
would upset their metabolic rates. Therefore, carbon-14 labeled fructose was used to 
follow the change in cellular uptake. The labeled fructose was incubated in tumor cells 
for 15 min because the uptake was in linear phase during this period of time. The 
amount of uptake was expressed as the total counts per mg proteins. 
For MCF-7 cells, the fructose uptake was reduced by the anti-Glut5 
oligonucleotide after one day of transfection (Fig 3.25). The amount of fructose intake 
was significantly lower when compared with that of the sense-sequence control. For two 
days after transfection, the fructose uptake was also lower in antisense treated cells (Fig 
3.26). For MDA-MB-231 cells, similar results were observed. The fructose uptake in 
antisense treated cells was suppressed after one or two day transfection when compared 
with that of the sense control. This was consistent with the findings that the Glut5 
proteins were less during this period of time. 
On the other hand, the glucose transport of tumor cells was also investigated. If the 
antisense oligonucleotide specifically targeted to Glut5, whether this alteration in GlutS 
would lead to any change in other glucose transporters was not known. From figure 
3.27 and 3.28, the glucose transport of both MCF-7 and MDA-MB-231 cells were not 
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affected by the addition of antisense oligonucleotide treatment but there was reduction 
in fructose uptake. These results implicated that the decrease in fructose uptake did not 
cause any compensatory change in glucose transport. Glut5 seemed to be only affecting 
glucose transporter. It was also consistent with other findings that Glut5 was mainly a 
fructose transporter rather than a glucose transporter. 
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Fig 3.25 The effect of Gluts antisense oligonucleotide on the fructose uptake of 
both MCF-7 and MDA-MB-231 cells after one day of recovery. 
Using i4c-fmctose followed the uptake of fructose in these cells. After one day of 
transfection, 0.5 i^Ci ^"^C-fructose in PBS was incubated with cells for further 15 min. 
The amount of fructose uptake was expressed as counts per |Lig protein content. There 
was a significant reduction in antisense treated cells when compared with that of sense-
treated cells. Data were expressed as the mean value of 4 replicates 土S.D. The 
significance of the differences were analyzed by student's t-test (* p<0.01; ** p<0.001). 
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Fig 3.26 The effect of Gluts antisense oligonucleotide on the fructose uptake of 
both MCF-7 and MDA-MB-231 cells after two days of recovery. 
The amount of fructose uptake was lower in antisense treated cells than in the sense-
sequence treated one. The reduction in fructose uptake indicated that the Glut5 
expression was suppressed after the treatment of antisense oligonucleotide. Data were 
expressed as the mean value of 4 replicates 土S.D. The significance of the differences 
were analyzed by student's t-test (* p<0.03; ** p<0.001). 
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Fij; 3.27 The effect of GlutS antisense oligonucleotide on the glucose uptake of 
MCF-7 cells after one and two days of transfection. 
2-Deoxy-D-[ 1- -^ 11] glucosc was used to follow the glucosc uptake in MCF-7 cells. The 
cells were incubatcd with 0.5 |.iCi for further 15 min after rccovcry from transfcction at 
time indicated. The amount of glucosc uptake was expressed as count per protein 
conlcnts. When compared with sense oligonucleotide (S), the glucosc uptake in 
antisense (AS) ireatcd cclls was similar. The glucosc uptake was not affcctcd by Gliit5 
aiuisense oligonucleotide. Data were expressed as the mean value of 4 rcplicatcs 土S.D. 
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Fig 3.28 The effect of GlutS antisense oligonucleotide on glucose uptake in MDA-
MB-231 cells after one and two days of transfection. 
The cells were incubated with 0.5 |LiCi 2-Deoxy-D-[l-^H] glucose for further 15 min 
after recovery from transfection at time indicated. The amount of glucose uptake was 
expressed as count per protein contents. There were no significant differences on 
glucose uptake between the sense (S) and antisense oligonucleotide (AS) treated cells 
after one or two days of recovery. Data were expressed as the mean value of 4 replicates 
士S.D. 
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3.10 Change of the phosphofructokinase-1 (PFK-1) activities in MDA-
MB-231 cells 
The metabolic fate of fructose after entry of the cells is glycolysis. Fructose would 
be phosphorylated by hexokinase to form fmctose-6-phosphate. To commit glycolysis, 
it should be further phosphorylated to form fructose-1,6-bisposphate which was 
catalyzed by phosphofructokinase-1 (PFK-1). It is one of the critical enzymes that plays 
a regulatory role in glycolysis. Changes in the activity of PFK-1 would be accompanied 
with changes in glycolytic rate. From the above results, there was evidence that the 
Glut5 protein expression level was suppressed after transfection with antisense 
oligonucleotide and resulted in decrease of fructose uptake. As one of the substrates in 
glycolysis, these changes would affect the metabolic rate of fructose and so the 
glycolysis. Any changes in the glycolytic rate could be reflected by the changes in 
phosphofructokinase activities. Therefore, the PFK activity of the MDA-MB-231 cells 
was investigated. Firstly, the cytosolic fraction of cells was extracted by centrifugation. 
The activity of PFK was determined by accompanying with several enzymes as 
described in Materials and Methods. In MDA-MB-231 cells，it was found that PFK 
activity was lower in antisense treated cells compared with the serum-free and sense 
sequence treated cells (Fig 3.29). On the first day of recovery, the reduction in PFK 
activity was slight but the change became more significant when compared with that of 
the sense control on the second day of recovery (p<0.02). The enzyme activity in sense 
oligonucleotide treatment was more or less the same as the serum-free medium 
treatment. It seemed that anti-Glut5 oligonucleotide treatment could lower the rate of 
glycolysis. This lower glycolytic rate could be observed after one or two days of 
transfection. This reduction in the metabolic rate may be responsible for the 
antiproliferative effect exerted by the antisense oligonucleotide. 
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Fig 3.29 The PFK activity of MDA-MB-231 cells after antisense treatment. 
The measurement of PFK activity was described in details in Materials and Methods. In 
brief, the cytosolic fractions of the cells were collected and the PFK activities were 
measured by coupling with a number of following enzymes. Serum-free medium (SF), 
sense sequence (S) and antisense oligonucleotide (AS) treated MDA-MB-231 cells were 
investigated after one and two days of transfection. Data were expressed as the mean 
value of triplicate 土S.D. The significance of the differences were analyzed by student's 
t-test (* p<0.02) 
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3.11 Measurement of the change in the intracellular pH of the breast 
tumor cells 
As the uptake of fructose was affected after the treatment with antisense 
oligonucleotide, it was speculated that the metabolism of fructose would be affected. 
Since the major metabolic pathway of fructose was through glycolysis, reduction of 
substrate supply would affect the glycolytic rate. Normally, decrease in glucose supply 
would increase the production of lactate in order to maintain the energy supply. In 
breast cancer cells, it was found that one of the principal products of glycolysis was 
lactate (Kallinowski et al,, 1988). On the other hand, the change in lactate concentration 
would be accompanied with a change in intracellular pH of the cells. Increase in the 
lactate production accompanying with H+ would decrease the intracellular pH. Thus, it 
was worthy of measuring if there was any change in the intracellular pH after inhibition 
of fructose uptake by the antisense oligonucleotide. This could reflect the change in 
lactic acid production and so the glycolytic rate indirectly, although further investigation 
was needed to prove it. 
BCECF was used as a fluorescent indicator for intracellular pH. The 
acetoxymethyl (AM) ester derivative was used to permit cell penetration. It is 
nonfluorescent unless the AM group is cleaved by the non-specific esterase. Native 
BCECF has 4-5 negative charges at pH 7-8, aiding intracellular retention. The pK^ is 
7.0 which is suitable for measurement of intracellular pH over physiological conditions 
ranged from 6.8 to 8.0. The spectral response of BCECF undergoes an excitation shift 
on ion binding known as isosbestic point. At this point, two species such as ion-free and 
ion-bound forms are in equilibrium. The isosbestic point of BCECF is at 439 nm in 
excitation measurement. When the fluorescence is excited at the isosbestic point, the 
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Fig 3.30 Changes in the intracellular pH in both MCF-7 and MDA-MB-231 cells 
after one day recovery. 
Cells were incubated with the pH indicator B C E C F in 2 |LIM for 20 min. The cells were 
then trypsinized and the resuspended in HBSS. The intensity ratio at excitation 
wavelengths 490 nm and 440 nm was then measured at emission wavelength 535 nm. 
Band pass 2.5 nm was used. The data were expressed as mean value of triplicate 士S.D. 
The significance of the differences were analyzed by student's t-test (* p<0.02, ** 
p<0.01). 
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Fig 3.31 The calibration curve of the intracellular p H of MCF-7 and MDA-MB-231 
cells. 
The internal and external pH of the loaded cells was first equilibrated with isosmotic 
buffer containing 130 mM KCl and 1 mM MgCl� with 2 j^ M nigericin. A 5-min 
incubation was sufficient. Buffers ranged from 6.4 to 8.0 were used. The intensity ratio 
at excitation wavelengths 490 nm and 440 nm was then measured at emission 
wavelength 535 nm. A band pass of 2.5 nm was used. The data were expressed as mean 
value of triplicate 士S.D. 
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Fig 3.32 Changes in the intracellular pH in both MCF-7 and MDA-MB-231 cells 
after two days recovery. 
Cells were incubated with the pH indicator BCECF in 2 j^ M for 20 min. The cells were 
then trypsinized and the resuspended in HBSS. The intensity ratio at excitation 
wavelengths 490 run and 440 nm was then measured at emission wavelength 535 nm. A 
band pass of 5 nm was used. The data were expressed as mean value of triplicate 土S.D. 
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intensity is directly proportional to the amount of dye in the sample and independent of 
the ion concentration. The intensity excited at any other wavelength depends both on 
the indicator concentration and the ion concentration. Because the intensities at any two 
wavelengths are expressed in arbitrary fluorescence units per mole of indicator, forming 
a ratio of the intensities which removes the indicator concentration dependence. 
Therefore, measurement of the excitation ratio at any two wavelengths of BCECF will 
be only dependent on the concentration of ions and reflect the pH value (Haugland, 
1993). The fluorescent intensity ratio increases as the intracellular pH increases. 
Firstly, 2 i^M of BCECF in HBSS was loaded with cells for 20 min. The cells were 
then harvested and the fluorescent intensity at 535nm excited at 490 nm and 440 nm 
was measured respectively. The intensity was calculated as ratios to illustrate the 
intracellular pH. From figure 3.30, the fluorescent intensity ratio in antisense treated 
cells was lower than that of serum-free and sense sequence treated controls after one 
day of transfection. In both MCF-7 and MDA-MB-231 cells, the change was significant 
(p<0.01 and p<0.02) when compared with the values of the sense controls. That meant 
the intracellular pH of the antisense treated cells was slightly lower than that of the 
sense controls. By calibration with ionophore nigericin (Fig 3.31), the pHj of MCF-7 
cells were found to be 7.0, 6.9 and 6.4 while the pHj of MDA-MB-231 cells were found 
to be 7.3，7.2 and 7.1 in serum-free, sense and antisense treated cells respectively. 
However, this subtle change could not be observed after incubation for one more day 
(Fig 3.32). The intensity ratio was more or less the same among the different treatments. 
Similar observation was obtained in both MCF-7 and MDA-MB-231 cells. The 
acidification of breast cancer cells by the GlutS antisense oligonucleotide could only 
last for one day. 
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4. Discussion 
4.1 The insights of GlutS antisense oligonucleotide into cancer therapy 
The potential of antisense oligonucleotides being a therapeutic agent has aroused 
wide concerns. The antisense oligonucleotide therapeutic strategy has caused deep 
impact on the traditional concepts on diagnoses and treatments of diseases. In traditional 
diagnoses, the classification of the diseases were mainly anatomical and descriptive 
basis in nature while the treatments were largely focused on the retrieval of the normal 
phenotypes or suppression of the adverse effects. As the increasing knowledge on 
human genome, the functions of specific genes have been characterized. Therefore, 
molecular characterization of the diseases has become a popular research project. 
Moreover, the gain in the gene sequence information and the genetic basis of diseases 
revolutionize the ways of treatments. Scientists began to 'treat' the genes that drive the 
disease processes rather than counteracting factors leading to the phenotypes. The 
therapeutic targets have changed from the protein level to the genetic level. 
Antisense oligonucleotides are short stretches of synthetic, chemically modified 
nucleic acids. They are designed to hybridize to complementary mRNA sequences by 
Watson-Crick base pairing rules in order to block the translation of proteins from the 
mRNA transcripts. By this means, the function of the gene is suppressed (Murray & 
Crockett, 1992). Since genetic level is thought to take a primitive role in causing a 
phenotype, it is believed that this antisense mechanism is more effective and profound. 
Another attractive point on application of antisense oligonucleotides is that they can 
bind specifically to the target mRNA without affecting other messengers. In principle, 
the specificity of antisense usage is so high that antisense oligonucleotides can even 
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distinguish between one base difference (Mercatante & Kole，2000). On the other hand, 
there are a wide variety of application points for antisense oligonucleotides to act. From 
transcription to translation of a gene, any interference on RNA processing would lead to 
downregulation of the corresponding protein. In fact, downregulating the gene 
responsible for a particular disease has been investigated for exploitation as a new 
therapeutic agent (Giovine et al” 1998; Miayake, 2000). The target gene can be critical 
for disease processing, such as oncogenes, or other genes vital to cell viability. 
In this study, the potential of antisense oligonucleotide on tackling breast tumor 
cells was investigated. Since alteration of glucose transport would affect the growth of 
tumor cells while the transport is mainly mediated by glucose transporters. GlutS 
transporter, a breast tumor specific transporter, was chosen to be the target because the 
normal breast tissues do not express Glut5. A recent research has found that suppression 
of facilitative glucose transporter 1 mRNA could suppress the growth of a gastric cancer 
cell line (Noguchi et al” 2000). It was speculated that upset of the Glut5 mediated 
transport would also inhibit the growth of breast cancer cells. To verify this point of 
view, 15-base and 21-base oligomers were designed to be complementary to the start 
codon of the Glut5 mRNA in order to suppress the expression of Glut5 proteins in 
human breast cancer cells. Two different breast tumor cell lines, MCF-7 and MDA-MB-
23 1 cell lines, were used in order to mimic both the hormone dependent and hormone 
independent phenotypes respectively. 
4.2 The uptake pattern of GlutS antisense oligonucleotides in breast tumor cells 
Firstly, the uptake of the antisense oligonucleotides was examined. FITC 
conjugated oligonucleotides were incubated with cells in serum-free medium. In both 
tumor cell lines, the trend of uptake was similar. The uptake of oligomers was time 
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dependent. More oligonucleotides were internalized as the time of incubation increased. 
There was a rapid increase in the first 3 hours and it slowed down after then. Due to the 
negative charges on oligodeoxynucleotides, charge-charge repulsion with cell 
membrane would give rise to a low efficacy of uptake of oligonucleotides that usually 
limited the application and success of antisense therapy. A number of methods were 
introduced to increase the internalization of oligonucleotides. In this study, a cationic 
lipid, lipofectin, was used to enhance the uptake. Positive charges on lipofectin could 
interact with the negative charges on the sulfur groups of oligomers to form complex. 
From our results, the lipofectin did enhance the uptake of oligomer in both cell lines. 
For 15-base antisense oligonucleotides, the uptake was increased from at least 2 folds in 
MCF-7 cells to 53 folds in MDA-MB-231 cells when lipofectin was used. It seemed 
that the uptake efficacy of MDA-MB-231 cells was higher than that of MCF-7 cells at 2 
|aM of antisense oligonucleotide. Moreover, the uptake process in these cell lines was 
saturable. At 2 i^M, there was no further increment after 15 hr transfection even when 
lipofectin was used. Receptor-mediated endocytosis was one of the proposed 
mechanisms mediating the transport of oligonucleotides (Yakubov et al., 1989) and this 
process also occur in a saturable manner. On the other hand, when unlabeled 
oligonucleotides were co-incubated with labeled ones, the unlabeled oligonucleotides 
would hinder the entry of labeled oligonucleotides which were carried by lipofectin. 
This may be due to lipofectin complexed oligonucleotides, at least in some extent, 
shared with native oligonucleotides for some routes of entry. These routes included 
passive diffusion and pinocytosis. Or, not all the labeled oligonucleotides were 
complexed with lipofectin. Part of these 'free-form' oligonucleotides were hindered to 
enter the cells because of the competition of unlabeled oligonucleotides. The mixing 
ratio between lipofectin and oligonucleotide were not optimized in this study and this 
was adjustable in different cell lines (De Lima et al., 1999). This may explain why the 
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difference in the uptake efficacy of lipofection between the two cell lines was so great. 
However, since this study was mainly focused on the effect of antisense oligonucleotide, 
the optimized condition were not investigated. 
In addition, the pattern of uptake of 21-base oligomers was different between these 
two cell lines. It seemed the uptake process occured somehow in a cell-specific manner. 
In MCF-7 cells, the internalization efficacy was higher than that of 15-base oligomers 
while the uptake efficacy in MDA-MB-231 cells was lower in 21-base oligomers. The 
length may also be attributed to the difference in uptake pattern. Several bases 
difference could affect the efficacy of uptake of oligonucleotides. 
4.3 Stability of antisense oligonucleotide during transfection 
Stability of antisense oligodeoxynucleotide was important for successful 
transfection. Native oligodeoxynucleotide was relative liable to degradation. 
Modifications were introduced in order to make the oligonucleotide more resistant to 
nucleases in the medium. Phosphorothioation was used in this study and it was found 
that phosphorothioate oligonucleotide was more stable than the native one in 
cytoplasmic extracts and human serum (Akhtar et al., 1991). The stability of the 15-
base antisense oligonucleotide in serum-free medium was investigated. The integrity of 
the 15-base oligonucleotide was mostly maintained over the period of transfection. 
Some findings suggested that liposomal delivery could protect oligomers from 
degradation (Capaccioli et al., 1993). However, the addition of lipofectin did not affect 
the integrity after 15 hr incubation in serum-free medium. It may be due to the majority 
of oligonucleotides that remained intact even in native forms. After all, maintenance of 
the integrity of oligonucleotides could be guaranteed during the transfection period. 
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4.4 Effects of GlutS antisense oligonucleotide on MCF-7 and MDA-MB-231 cells 
It was found that the Glut5 antisense oligonucleotide was effective on inhibiting 
the growth of breast tumor cells. In both 15-base and 21-base oligonucleotides, GlutS 
antisense oligonucleotides exerted antiproliferative effect on both MCF-7 and MDA-
MB-23 1 cells in a dose dependent manner. The increase in antisense oligomer 
concentration would lead to an increase in inhibition relative to the serum-free medium 
treated control. Sense sequence treated cells were used to illustrate the non-specific 
effect. This non-specific effect did inhibit cell growth although it was relatively low 
compared with that of antisense treatment. However, it was more adverse in higher 
concentrations of oligonucleotides. There were a variety of proteins with which 
oligonucleotides interact in an apparently sequence-independent manner, such as DNA 
polymerases (Bennett, 1998; Roush, 1997). It was then preferred to using a lower 
concentration of oligonucleotides with certain effectiveness in order to ensure the 
specificity of antisense action. This concentration ranged from 2 to 5 [iM. The 
effectiveness of the antisense oligonucleotides was similar in both cell lines. This is 
unlikely true for tamoxifen because it is more useful on inhibiting ER positive tumor 
cells but spare ER negative cells. 
The effect exerted by the 15-base antisense oligonucleotide was further 
investigated to give a clearer picture on the mechanisms of GlutS antisense 
oligonucleotides. From the trypan blue exclusion assay, it seemed that the 
antiproliferative effect did not occur after 15 hr of transfection. There were no 
remarkable toxicity observed in the usage of lipofectin after it was complexed with 
oligodeoxynucleotides. The number of cells after transfection was more or less the same 
in both serum-free medium treated control and antisense treated sample. The two 
different treated cells then grew at different rates and resulted in differences in the 
93 
Antisense Inhibition of Glucose Transporter 5 on Breast Tumor Ccl Is 
number of cells counted in day one and day two after transfection. The growth rate 
observed in antisense treated cells was obviously lower. This phenomenon was again 
confirmed by using [methyl-^H] thymidine incorporation. The growth rate was 
measured on the first and second day after recovery from transfection and was 
interpreted as counts per |ag of cell extract. In both MCF-7 and MDA-MB-231 cells, 
Gluts antisense treatment could lower the rate of replication of chromosomes (S phase) 
than that of serum-free and sense-sequence controls. This indicated that antisense 
oligonucleotide made the breast tumor cells grow less actively than the other two 
controls during the same period of time. Although the non-specific effect exerted by 
sense sequence would sometimes lower the rate also, the differences between it and the 
specific effect carried out by antisense oligonucleotide were found to be significant. 
These results reaffirmed that Glut5 antisense oligonucleotide could exert an 
antiproliferative effect on the breast tumor cells. 
To be a specific therapeutic agent, it should carry out its effect on the target pre-
selected. In cancer therapy, many drugs make use of the principle that tumor cells 
possess a higher rate of proliferation. Blockade of any dividing processes would be 
more adverse to cancer cells than normal cells. However, side effects happened 
inevitably. For the anti-Glut5 oligonucleotide, it should only affect cells with GlutS 
expression while sparing those cells without Glut5 proteins unaffected. To verify this 
point, non-Glut5 expressed HepG2 cells was used to treat with the 15-base antisense 
oligonucleotide. Most of the effect exerted by Glut5 antisense was likely in a non-
sequence specific manner because the percentage of survival in antisense treatment was 
similar to that of the sense oligonucleotide. The antiproliferative effect was much less 
than that on Glut5 expressed MDA-MB-231 cells. It is important to make sure that anti-
GlutS oligonucleotide would be specific to breast tumor cells without affecting the 
surrounding normal breast cells and other epithelial cells. Then the side effects of this 
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treatment could be minimized. Although the specificity of Glut5 antisense 
oligonucleotide was promising in in vitro experiment, the effect of this antisense 
oligonucleotide in vivo was still an open question. 
In cell cycle analysis, unexpected results were obtained. For agents that inhibited 
the growth of cells, they might affect the distribution of the cell cycle pattern. Usually, 
most of these agents would cause cell cycle arrest in G1 phase. For example, tamoxifen, 
one of the common antiestrogens, inhibited the growth of breast cancer cells by 
blocking the transition from G1 to S phase (Lykkesfeldt et al” 1984). Thus, majority of 
the cell population would be measured in G1 phase. It was speculated whether the 
antiproliferative effect of Glut5 antisense oligonucleotide would also cause G1 phase 
arrest in breast tumor cells. From the results obtained, there was no remarkable G1 
phase arrest observed. The cell population of antisense oligonucleotide treatment in G1 
phase was more or less the same as the cell population of either serum-free medium 
treated or sense-sequence control. There was only one time point (two days after 
transfection) that showed similar phenomenon in MCF-7 cells. For MDA-MB-231 cells, 
the cell population in the S phase of the antisense treatment was less than that of sense 
and serum-free controls after recovery for two days. This was consistent with the results 
in thymidine incorporation. However, the antiproliferative effect measured in thymidine 
incorporation was not as clear as measuring by this means. 
It was also shown that the action mechanism of antisense oligonucleotides did not 
lead to apoptosis in breast tumor cells. Apoptosis was a process of programmed cell 
death and would lead to DNA fragmentation. The nuclear DNA extracted after antisense 
treatment was shown to be intact in both cell lines. No DNA ladder was observed after 
one and two days of transfection. Apoptotic bodies could not be detected under 
microscopy. 
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4.5 Proofs of undergoing antisense action mechanism 
The action mechanism of antisense oligodeoxynucleotide is to inhibit the 
translation of the pre-selected gene. In the cytoplasm, the antisense oligonucleotides 
bind to its complementary sequences on mRNA through Watson-Crick base pairing 
(Curcio et al., 1997). The binding should be a highly specific and rapid manner. After 
the binding, the oligonucleotide-RNA duplex can serve as the substrate for RNase H. 
RNase H is a ubiquitous enzyme that is more abundant in nucleus but can also be found 
in the cytoplasm. It is thought to involve in reverse transcription and DNA replication 
(Walder & Walder, 1988). The enzyme can digest the short RNA primers used to initiate 
DNA synthesis. The eukaryotic cells contain multiple forms of RNase H. Two distinct 
I I 
forms have been purified. They are Mn - dependent and Mg - dependent RNase H 
(Sawai et al., 1981). They are highly specific for RNA complexed to DNA while DNA 
and single-stranded RNA is not degraded. Not all the modifications of oligonucleotides 
can be the substrates for RNase H. For phosphorothioate oligomer, it was found that 
extensive degradation could be triggered (Zamora-Leon et al,, 1996). Through the 
action of RNase H, the inhibition of antisense oligonucleotide becomes irreversible and 
rapid (Capaccioli et al,, 1993). This action also potentiated the effect of antisense 
oligonucleotide because the bound oligonucleotides could be released and bound to 
another mRNA. The degradation of RNA would result in reduction in the RNA level. 
By RT-PCR, the amounts of Glut5 mRNA can be measured semi-quantitatively. From 
our results, the suppression of Glut5 mRNA could be observed as soon as 5 hr after 
transfection. The reduction of mRNA could only be observed in antisense treatment. 
This illustrated that Glut5 antisense oligonucleotide bound to target RNA specifically 
but not the sense oligonucleotide. The suppression of Glut5 mRNA lasted to 48 hr after 
transfection. The level of mRNA recovered back to normal level as the serum-free and 
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sense-sequence controls for one day further. Moreover, the trend of changes in mRNA 
level was similar in both tumor cells. It was, nevertheless, difficult to compare the level 
of change between the two tumor cell lines because the PGR products were normalized 
for each cell line separately. It could only say that the suppression was most pronounced 
after 24 hr of transfection in both cell lines. The level of GlutS mRNA then increased 
gradually. This may be due to the beginning of degradation of the antisense 
oligonucleotides inside the cells. A single dose of Glut5 antisense oligonucleotide could 
only last for about two days. Moreover, the level of Glu5 mRNA in antisense treatment 
seemed to be upregulated at 72 hr after transfection. 
Besides the RNase H mediated arrest in translation, the binding of the antisense 
oligonucleotide could exert steric effect to inhibit protein synthesis. Both mechanisms 
mediated suppression of mRNA and would inevitably lead to a decline in the 
corresponding protein expression. The ultimate goal of antisense mechanism is to affect 
the gene at protein level. Through the changes in protein level, the phenotypes or 
physiological conditions of cells would be affected. Therefore, the target of Glut5 
antisense oligonucleotide is to suppress the Glut5 protein expression in both tumor cells. 
The amount of Glut5 proteins was lower in antisense treated cells than the amount in 
sense oligonucleotide control. The suppression of Glut5 proteins could be observed on 
the first and second day after the transfection. In MCF-7 cells, the degree of suppression 
of Gluts protein was less than the suppression in MDA-MB-231 cells on the first day 
after transfection. However, as the recovery period kept going, this subtle inhibition of 
protein synthesis in MCF-7 cells become more pronounced on the second day after 
transfection. The transition of the inhibitory effect from mRNA to protein level seemed 
to be slower in MCF-7 cells. Moreover, it should be noted that there was a slight 
difference observed in sense treatment when compared with the serum-free treatment. 
This may be due to the interaction between the sense oligonucleotide and the regulatory 
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proteins involved in protein synthesis. This resulted in a non-specific effect observed in 
the sense-sequence treatment. 
4.6 Physiological changes in breast tumor cells after antisense treatment 
After it was demonstrated that the antisense oligonucleotide did affect the 
translation of Glut5 gene, the ensuing physiological changes that led to the 
antiproliferative effect was under investigation. Being a transporter, it was 
straightforward to think that the suppression of GlutS would inevitably inhibit the 
transport capacity of this transporter. GlutS is one of the members of facilitative sugar 
transporters. It has a high affinity for fructose but is a poor candidate for glucose 
transport (Mueckler, 1994). Glut5 is a highly tissue-specific transporter. It is still an 
unknown question why Glut5, which is absent in normal breast tissue, is expressed in 
human breast carcinoma. We speculate that breast tumor cells express Glut5 in order to 
gain metabolic advantage over surrounding tissues. Fructose represents an increasing 
proportion of dietary carbohydrate especially in the Western world in which there is a 
higher incident rate of breast carcinoma (Department of Health, 1998). Gaining the 
ability of fructose uptake therefore provides an alternative way of absorbing energy. In 
addition, fructose is a good substrate for glycolysis which is the principal metabolic 
pathway in cancer cells. 
Glut5 antisense oligonucleotide was proposed to suppress the expression of Glut5 
and took over this advantage. It was found that the fructose uptake was inhibited after 
the suppression of GlutS in protein level. [^ "^ C] fructose was used to illustrated this point. 
After antisense treatment, the fructose uptake in both MCF-7 and MDA-MB-231 cells 
was significantly lower than the sense-sequence controls. The decrease in fructose 
uptake could be attained during the period of time in which the expression of Glut5 was 
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downregulated. If Glut5 was the only affected transporter, the uptake of glucose in these 
tumor cells should not be affected because the glucose capacity of Glut5 was found to 
be very low. As expected, the trend of glucose transport in these cells was similar 
between sense and antisense treatments. The differences were not significant no matter 
it was on the first or second day of transfection. These results indicated that Glut5 
antisense oligonucleotide affected fructose uptake only while sparing glucose transport 
unchanged. Downregulation of fructose uptake did not trigger any compensatory effect 
on glucose transport in order to restore the substrates supplying. 
D-Fructose is a six-carbon monosaccharide. It can be a straight chain or in the form 
of furanose. Fructose in the diet comes from both the fructose occurring naturally in 
food and the fructose added to food during processing and preparation with the use of 
sweeteners. By a survey, it represents 7-9 % of the energy intake in the United States 
(Zamora-Leon et al., 1996). Glycolytic pathway is the major metabolic pathway for 
fructose (Lehninger et al., 1993). Either it is in free form or derived from hydrolysis of 
sucrose and it can be phosphorylated by hexokinase to form fmctose-6-phosphate. The 
subsequent events are the same as the glucose participated in glycolysis (Fig 4.1). For 
the first step that fructose commits to glycolysis is the catalysis of fructose-6-phosphate. 
The reaction is catalyzed by phosphofructokinase-1 (PFK-1) in which fructose-6-
phosphate is converted into fructose-1,6-bisphosphate. In addition, PFK-1 is one of the 
key enzymes regulating the rate of glycolysis. Since the fructose uptake in breast tumor 
cells was suppressed after the cells were treated with Glut5 anitsense oligonucleotide, 
we proposed that the reduction in substrate supply would slow down the rate of 
glycolysis. This would reflect through the change in PFK activity. Therefore, the PFK-1 
activity in MDA-MB-231 cells was investigated. After one day recovery from 
transfection, the PFK-1 activity was lower in antisense oligonucleotide treated cells. 
However, the difference between the sense and antisense treatments was not significant 
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until the enzymatic activity was measured on the second day of recovery. Reduction in 
PFK activity was a good indicator for the slowing down in glycolytic rate. Glut5 
antisense oligonucleotide could reduce the uptake of fructose into the cells and lowered 
the glycolytic rate simultaneously. As PFK-1 catalysed the key step in glycolysis, the 
following steps in glycolytic pathway accompanied with the ATP production would also 
be prohibited. For tumor cells with rapid proliferation rate, it was found that slow down 
of glycolysis would upset their proliferation rate. As a result, the proliferation of the 
cells was inhibited (Zamora-Leon et al., 1996). This was similar to the observation after 
treating with the antisense oligonucleotide. 
Fructose 
i i w 
Fmctose-6-phosphate 
Pyruvate ^ Lactate 
PFK-1 1 r \ \ 






1,3-Bisphosphoglycerate — —— 3-Phosphoglycerate 
Figure 4.1 Metabolic pathway of fructose in glycolysis. 
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Normally, decrease in glycolytic rate, such as in anaerobic condition, would 
stimulate the production of lactic acid. The end-product of glycolysis would shunt more 
from pyruvate to lactic acid. By this means, reduced NAD could be converted to 
oxidized form in order to ensure the propagation of glycolytic pathway and so the ATP 
production. The increase in lactic acid production would lead to intracellular acidosis. 
This phenomenon has been demonstrated on heart tissue by alternating the blood flow 
in coronary artery (Neely et al., 1975). The same intracellular acidosis could be 
observed in breast tumor cells after antisense oligonucleotide treatment. The 
intracellular pH of both breast cancer cells become more acidic as indicated by using a 
sensitive pH indicator BCECF. The acidification of MCF-7 and MDA-MB-231 cells 
occurred after recovery from transfection for one day. This subtle change in intracellular 
pH was rapid and disappeared soon after one day. 
Many researches have suggested that there was a close relationship between the 
intracellular pH and proliferation. Cytosolic pH seemed to play a permissive role in 
cellular growth and proliferation. It has been found that growth factors like EGF would 
raise the intracellular pH (Moolenaar, 1986). This alkalization could initiate the growth 
and proliferation of different kinds of cells including Schwann cells and some tumor 
cells (Saunders et al., 1989; Horvat et al., 1993). This induced proliferation was blocked 
by acidification which was caused by Na+/H+ exchanger inhibitor amiloride or 
nigericin. Therefore, the antiproliferative effect exerted by Glut5 antisense 
oligonucleotide could be explained, at least in part, by the induction of acidification in 
the tumor cells. On the other hand, it was found that acidic pH could potentiate the 
inhibition on activity ofPKF (Opie, 1976). This may explain why the inhibition of PFK 
activity was more significant on the second day of recovery, i.e. one day after the 
detectable pH change. Moreover, most of these intracellular acidification recorded did 
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not last for a long time. It would disappear within several hours. This was why the 
acidification observed in the breast tumor cells could not be measured after two day of 
transfection. 
Up to this stage, Glut5 antisense oligonucleotide was found to exert an 
antiproliferative effect on the breast tumor cells. The effect on MDA-MB-231 cells 
seemed to be more pronounced than on MCF-7 cells. This may be due to the Glut5 
protein level was more suppressed in MDA-MB-231 cells. The effect was also 
promising although the detailed action mechanism leading to antiproliferation was still 
unknown. Further investigation on the metabolic changes within the cells should be 
done. Moreover, duration of the antiproliferative effect and blockade of the antisense 
effect would provide more information on how the antiproliferative effect was triggered. 
On the other hand, it was suitable to look further on the application of GlutS antisense 
oligonucleotide on in vivo experiment. It was worthy of investigation because it was 
important step for evaluation of the usage of GlutS antisense oligonucleotide in clinical 
cases. 
102 
Antisense Inhibition of Glucose Transporter 5 on Breast Tumor Cells 
5. Conclusion 
Antisense oligonucleotides have been applied on a wide variety of fields. These 
included investigation of the function of a gene and modification of gene expression. In 
this study, antisense oligonucleotide targeted to Glut5 was used to downregulate the 
expression of Glut5 on breast tumor cells. The Glut5 antisense oligonucleotide did 
suppress the Glut expression at both mRNA and protein levels. It was also found that 
concomitant reduction on fructose uptake could be detected on breast tumor cells. 
Moreover, antiproliferative effect was observed in both cell lines. This antiproliferative 
effect has a close association with the change in glycolytic rate and acidification of the 
intracellular environment. Nevertheless, there was no detectable feature to show that 
apoptosis was involved. To clearly illustrate the mechanism leading to antiproliferation, 
further experiments need to be done. 
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